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Stress is one of the leading predisposing factors for the onset of anxiety and 
depression. The mechanisms underlying stress vulnerability remain not fully understood 
and this gap significantly delays the advancement of the biomedical field. Pituitary 
adenylate cyclase-activating polypeptide (PACAP), a 38-amino acid peptide, has been 
proposed to regulate the stress response by acting at multiple levels. The central hypothesis 
of this work was that the PACAP system of the extended amygdala, a basal forebrain 
structure that includes the central nucleus of the amygdala (CeA) and the bed nucleus of 
the stria terminalis (BNST), plays a critical role in the physiological and pathological 
behavioral response to stress.  I found that central (intracerebroventricular) administration 
of PACAP in rats is able to produce a depressive-like endophenotype, as measured by 
increased current threshold for intracranial self-stimulation (ICSS), reduced preference for 
a sweet solution, and reduced time spent interacting with a novel animal in a social 
interaction test. I then went on investigating the brain structures and mechanisms 
contributing to PACAP-induced behavioral effects. I found that microinfusion of PACAP, 
but not VIP, into the CeA and BNST caused a dose-dependent increase in acoustic startle 
	
vii 
response (ASR), a rapid defensive reflex that is an index of stress. In addition, PACAP(6-
38) infusions into either of these structures was instead able to prevent the sensitization of 
ASR induced by footshock stress, in line with the observation that the acute exposure to 
footshock stress induced a significant increase in PACAP, but not VIP, levels in both the 
CeA and the BNST. Finally, I found that the continuous recruitment of the PACAP system 
of the CeA was essential to the emergence of the negative outcomes of chronic stress. 
Indeed, chronic social defeat stress significantly increased PACAP levels in the CeA, but 
not the BNST; furthermore, viral vector-mediated knockdown of the PACAP receptor 
PAC1R in the CeA significantly attenuated decreased body weight gain, decreased 
saccharin consumption, and heightened anxiety-like behavior induced by chronic social 
defeat and also prevented the increase in CeA corticotropin-releasing factor (CRF) levels.  
The results obtained provide novel insights into the neurobiological mechanisms 
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CHAPTER ONE: INTRODUCTION 
 
Overview 
According to the Substance Abuse and Mental Health Services Administration as 
of 2016, an estimated 44.7 million adults aged 18 or older (1 in 6 adults) had a mental 
illness in the past year. Of these, major depressive disorder (MDD) afflicts 16.1 million 
adults, while anxiety disorders, the most prevalent mental illness, afflicts 40 million adults. 
Symptoms of these highly comorbid disorders include reduced ability to experience 
pleasure, or anhedonia (depression) and excessive fear of a stimulus, which can manifest 
with hypervigilance and hyperarousal (anxiety). While treatment options for anxiety and 
depression involve the targeting of monoamine systems and work for some individuals, 
30% do not respond to front-line monoamine drug treatment (Al-Harbi, 2012; Bystritsky, 
2006).  
One of the major risk factors for these disorders is stress. Stress is the physiological 
and psychological response to any perceived or potential demand. These demand, or 
stressors, lead to coordinated signaling by hormones, peptides and neurotransmitters in the 
peripheral and central nervous system (Joels and Baram, 2009). The stress response 
integrates information about the type and duration of the stressor, orchestrates recruitment 
of various neuronal cascades and, if necessary, triggers changes in gene and protein 
expression. The stress response, therefore, involves the execution of crucially important of 
actions, which are tapered to the severity and type of threat.  However, if this system is 




stress-responsiveness, and this can lead to the development of anxiety and depressive 
disorders (Gold et al., 1988; Heim and Nemeroff, 1999; McEwen, 2003; Newport and 
Nemeroff, 2000). Additionally, stress also exacerbates the symptoms of several psychiatric 
diseases (Kessler et al., 2005).  
The type of stressor and the duration of its presentation determines the recruitment 
of the specific hormones, neurotransmitters, and neuropeptides in particular brain regions, 
such as the hypothalamus, CeA, BNST, and the brainstem (for circuitry, Figure 1). These 
regions modulate the emotional and physical responses to stress leading to alterations in 
cognitive flexibility, changes in arousal, and perturbations in neuroendocrine and 
autonomic function. By elucidating the neurobiological mechanisms that regulate the 
physiological and pathological response to stress, we can develop better therapeutic options 
for treating psychiatric disorders. 
While a number of neurotransmitter systems are recruited by stress, this dissertation 
will focus on a neuropeptide, called pituitary adenylate cyclase activating polypeptide 
(PACAP). PACAP has been implicated in the regulation of both the central and the 
peripheral effects of stress. This chapter will provide details on both the acute and chronic 
stress responses and give background on the principal neural circuitry of stress. Key 
anatomical sites which convey information about threats and organize the response will be 
described, specifically the central nucleus of the amygdala (CeA) and the bed nucleus of 
the stria terminalis (BNST). Lastly, I will discuss the current literature on PACAP and its 




Fig. 1 Neural Circuitry of Stress Systems. Stress activates multiple brain regions, 
neurotransmitters and hormones in the central and peripheral nervous systems. NE, 
norepinephrine; CRF, corticotropin-releasing factor; ACTH, adrenocorticotropic hormone; 
CORT, corticosterone; PVN, paraventricular nucleus of the hypothalamus; BNST, bed 
nucleus of the stria terminalis; CeA, central nucleus of the amygdala; PBn, parabrachial 






The Stress Response 
Acute Stress Response 
When homeostasis of an organism is threatened by a psychological, environmental, 
or physiological stressor, the body executes physiological and behavioral adaptations to 
promote survival.  The autonomic and neuroendocrine responses to stress imply the 
activation of the sympathetic nervous system (SNS) and the hypothalamic–pituitary–
adrenal (HPA) axis, respectively.  
When the brainstem receives inputs that signal major homeostatic perturbations, it 
activates the SNS through the sympathoadrenomedullary pathway beginning with the 
triggering of preganglionic sympathetic neurons of the spinal cord. These neurons synapse 
and release acetylcholine on chromaffin cells of the adrenal medulla and on postganglionic 
neurons, resulting in the activation of nicotinic acetylcholine receptors. In turn, the 
postganglionic neurons and chromaffin cells of the adrenal medulla release norepinephrine 
(NE) (noradrenaline) and epinephrine (adrenaline) (for a review, see (Ulrich-Lai and 
Herman, 2009)). The secretion of these catecholamines leads to increased heart rate, 
sharpening of cognition, and acceleration of lung function, to name a few effects, and 
represent the classic “fight or flight” response first characterized by Walter Cannon and 
colleagues (Cannon, 1915). Although the SNS provides an immediate response to threats, 
this response is short-lived because of the compensatory activation of the parasympathetic 
branch.  
Besides the activation of the ANS, stressors also initiate the response of the HPA 




parvocellular subdivision of the paraventricular nucleus of the hypothalamus (PVN).  
These neurons synthesize and release corticotropin-releasing factor (CRF) into the pituitary 
circulation which, after reaching the anterior pituitary gland, stimulate the secretion of 
adrenocorticotropic hormone (ACTH) (Alonso et al., 1986; Antoni, 1986). The ACTH 
released into peripheral circulation stimulates the adrenal cortex and the secretion of 
glucocorticoids (corticosterone in rodents, cortisol in humans), which bind 
mineralocorticoid (MR) and glucocorticoid (GR) receptors. Glucocorticoids regulate 
metabolic, cardiovascular, immune, and behavioral functions and modulate the activity of 
the HPA axis through a negative feedback system at the level of the hypothalamus and 
pituitary gland in order to return the body to basal conditions (Sapolsky et al., 2000).   
Glucocorticoids also play a role in extrahypothalamic regions, such as the CeA, by 
modulating the behavioral response to stress and by regulating (usually via a positive 
feedback) CRF expression (Makino et al., 1994; Shepard et al., 2000).  It is important to 
note that the hypophysiotropic neurons of the PVN are innervated by numerous afferent 
projections, including brainstem, CeA, and BNST, but that these regions can generate and 
mediate stress-responses independently from the HPA axis (Herman et al., 2003; Muller et 
al., 2003).  These forebrain limbic structures, particularly the CeA, regulate the emotional 
and behavioral responses to stress and produce the anxiety state necessary to bias attention 
towards the threatening stimulus and away from less critical stimuli. In fact, the association 
of an emotional response to fearful or anxiety-provoking stimuli requires CeA activation 
(LaBar et al., 1998).  




(PFC) that coordinate the brain’s activity for effective regulation of behavior, thought and 
emotion (Arnsten, 2009). During presentation of a threat, PFC basal function is 
downregulated, consequently allowing the amygdala to increase in activity thus allowing 
the emotional or anxiety response to occur (Simpson et al., 2001). Furthermore, the 
disinhibition of the amygdala allows for CRF-containing neurons of the CeA to stimulate 
the HPA axis, locus ceruleus–norepinephrine system and the sympathetic nervous system 
(Aston-Jones and Cohen, 2005; Brown et al., 1982). While non-aberrant function of the 
stress response is crucial to understanding the pathology of stress-related disorders, we 
must also elucidate the mechanisms by which the stress response becomes maladaptive.  
 
Dysregulation of the Stress Response in Anxiety and Depressive Disorders 
Under physiological conditions, following exposure to stress, physiological and 
behavioral homeostasis is eventually restored in the body and the brain.  Under conditions 
of excessive or prolonged stress, when the cost of reinstating homeostasis is too high the 
organism responds with “allostatic” changes.  Allostasis is, therefore, the mechanism of 
the organism responsible for maintaining homeostasis through adaptive changes (McEwen, 
1998). This allostatic load, which is specific to what an individual can tolerate, leads to 
detrimental physiological and psychological consequences.  
Alterations in volume of key stress brain regions and in HPA-axis activity have 
been observed in mood disorders, confirming the key role of maladaptive stress responses 
in increasing the susceptibility to these disorders (de Kloet et al., 2005). Evidence from 




of glucocorticoid receptors throughout the limbic forebrain (Klok et al., 2011; Perlman et 
al., 2004). Individuals with Posttraumatic Stress Disorder (PTSD) exhibit higher levels of 
CRF in cerebral spinal fluid (CSF) compared to healthy controls (Baker et al., 1999); 
diurnal plasma cortisol levels .are generally decreased, while an enhanced cortisol 
suppression to certain doses of dexamethasone is observed (Bremner et al., 2003; de Kloet 
et al., 2006; Yehuda et al., 1994). Additionally, patients with MDD exhibit both elevated 
plasma cortisol and elevated CSF CRF, suggesting that CRF hypersecretion is, at least in 
part, responsible for the hyperactivity of the HPA axis in these individuals (Nemeroff et 
al., 1984). While it is still not clear what causes the hypersecretion of CRF, per se, evidence 
has suggested that hyperactivation of the amygdala could be responsible (Drevets et al., 
1992).  
 
Stress Neurocircuitry  
In order to understand the neural circuits that modulate the stress response, 
preclinical research employs different types of stressors, including restraint, footshock, 
noise, and social defeat, among others. While these various stressors trigger brainstem and 
hypothalamic systems in order to activate the HPA axis and SNS, they also cause 
widespread activation of limbic forebrain structures (Lopez et al., 1999), which trigger 
specific behavioral responses, such as anxiety, vigilance, fear, etc. (Cullinan et al., 1995; 





Central Nucleus of the Amygdala 
The CeA is part of the extended amygdala, a basal forebrain structure with 
overlapping afferents and efferents and similar cytoarchitecture (Alheid and Heimer, 
1988). The CeA is implicated in behavioral, autonomic, and neuroendocrine responses to 
stress and its function is associated with fear conditioning, aversive learning, and anxiety-
like behavior (Davis, 1992). The CeA integrates sensory information about threats from 
the environment and sends projections to various effector regions such as the 
hypothalamus, the cortex, and the brainstem nuclei to trigger the appropriate responses 
(Davis and Shi, 2000). Lesions of the CeA attenuate stress-induced HPA axis activation, 
while stimulation of the CeA facilitates it (Beaulieu et al., 1986; Prewitt and Herman, 
1994). Additionally, chronic-stress induced increases in anxiety-like behavior is blocked 
by CeA lesions (Ventura-Silva et al., 2013). 
The CeA is considered the main stress output of the amygdaloid complex, and it 
receives input directly from glutamatergic neurons of the basolateral amygdala (BlA) and 
also BlA input through GABAergic neurons of the intercalated cells (ITC) (Duvarci and 
Pare, 2014).  The CeA also receives afferents from brainstem regions, such as the 
parabrachial nucleus (PBn),, the ventral tegmental area (VTA), the locus coeruleus (LC), 
the nucleus of solitary tract (NTS), and the periaqueductal gray (PAG), structures involved 
in stress function, pain, and reward (Cassell et al., 1999). 
The GABAergic projections of the CeA to the PAG co-localize with CRF and 
Substance P and are critical to produce the physiological responses to fearful and painful 




monosynaptic projections to the PVN which regulate the HPA axis function (Feldman and 
Weidenfeld, 1998; Gray et al., 1989). CeA projections onto norepinephrine-containing 
neurons in the LC create a feed-forward control that is activated during stress (Koob, 1999). 
Lastly, CeA projects to the BNST, and this pathway has been implicated in the 
neurobehavioral responses to chronic stress (Jasnow et al., 2004), as well as to the dorsal 
part of the VTA (Fudge et al., 2017). 
 
Bed Nucleus of the Stria Terminalis 
The BNST is also part of the extended amygdala and similar to the CeA, contains 
CRF-expressing neurons (Morin et al., 1999), is implicated in mediating anxiety and stress 
responses (Walker et al., 2003), and is necessary for retention of contextual fear memories 
(Sullivan et al., 2004).  CRF microinfusions into the BNST produce rapid and large 
increases in startle response (Davis et al., 1997) and produce anxiety-like behavior in the 
elevated plus maze (Sahuque et al., 2006). The BNST and CeA do vary on the types and 
duration of stressors they respond to, such that the BNST  is thought to mediate 
unconditioned arousals to bright light (Walker and Davis, 1997b), predator odor (Fendt et 
al., 2003), and long-duration conditioned stimuli previously paired with shock (but not 
short-duration conditioned stimuli) (Waddell et al., 2006).  
The BNST is a connective center between BlA, CeA, and PVN and brain reward 
regions as VTA and nucleus accumbens (NAc) (Stamatakis et al., 2014). Major 
glutamatergic inputs to the BNST include PFC, BlA, hippocampus, and VTA (McDonald, 




et al., 2012). The BNST receives strong peptidergic inputs that modulate its activity, 
including CRF, neuropeptide Y (NPY), dynorphin, and orexin,, while it also has the 
potential to release CRF locally (Shepard et al., 2006). The BNST modulates the HPA axis 
activity through direct projection to the PVN (Dong et al., 2001; Roland and Sawchenko, 
1993). This, along with the observation that microinfusion of CRF receptor antagonists in 
the BNST blocks systemic CRF-induced anxiety-like behavior (Lee and Davis, 1997), 
further suggests that the BNST is critical in regulating anxiety-like states.  
 
Corticotropin-Releasing Factor (CRF) 
Corticotropin-releasing factor (CRF) is a 41-amino acid neuropeptide which 
initiates the neuroendocrine responses to stress by stimulating the synthesis of ACTH in 
the pituitary gland (Vale et al., 1981). The CRF system has multiple functions, including 
the regulation of anxiety and feeding, and the stimulation of the SNS (Bale et al., 2002). 
CRF is highly expressed in the PVN as well as in the CeA and the BNST, where it 
contributes to the extra-hypothalamic regulation of the stress response (Swanson et al., 
1983).  CRF acts via its class B subtype G protein-coupled receptors (GPCRs) CRFR1 and 
CRFR2 (Chen et al., 1993; Lovenberg et al., 1995). CRFR1 and CRFR2 have distinct 
localization in the CNS: CRFR1 is found abundantly in cerebral cortex, cerebellum, 
amygdala, medial septum, brainstem and anterior pituitary, while CRFR2 is highly 
expressed in lateral septum and ventromedial hypothalamus (Hauger et al., 2003). While 
CRFR1 activation is thought to contribute to the anxiogenic action of CRF, CRFR2 




differences are demonstrated by studies on mice deficient in CRFR1 displaying anxiolytic-
like behavior while mice deficient in CRFR2 displaying anxiogenic-like behavior (Bale et 
al., 2000; Smith et al., 1998).  
CRF activation in both the CeA and BNST has been shown to increase anxiety-like 
behavior (Lee et al., 2008; Rainnie et al., 2004). CRF central administration produces 
increases in acoustic startle response (ASR) in rats (Liang et al., 1992) while stress-induced 
increases in ASR are blocked by CRFR1 antagonism in the BNST (Walker et al., 2009). 
CRF receptor antagonism in the CeA reverses the anxiogenic-like effects of alcohol 
withdrawal (Rassnick et al., 1993).  Restraint stress increases extracellular CRF levels 
(Merlo Pich et al., 1995) and CRF mRNA (Herringa et al., 2004) in the CeA. CRF mRNA 
expression is increased in the CeA by a single restraint stress (Hsu et al., 1998), and chronic 
CRF overexpression in the CeA induces anxiety-like behaviors and activates the HPA axis 
(Flandreau et al., 2012). Importantly, CRF receptor antagonists require a background of 
high anxiety-like behavior to show anxiolytic-like activity (e.g. after restraint, swim stress, 
ethanol withdrawal or social defeat (Griebel et al., 1998; Heinrichs et al., 1994; Heinrichs 
et al., 1992; Menzaghi et al., 1994; Okuyama et al., 1999)), and this profile is explained 
with increased CRF release caused by those stressors in the CeA, the BNST, or both (Merlo 
Pich et al., 1995; Olive et al., 2002). CeA and BNST are highly interconnected, with the 
CeA sending dense CRF projections to the BNST (Sakanaka et al., 1986). Both the CeA 
and BNST send projections to the LC and the PBn, and in turn, the LC project back 
norepinephrine creating a feed-forward loop (Koob, 1999). While targeting CRF signaling 




treatments for stress-related disorder have been plagued with numerous failed clinical trials 
(Murrough and Charney, 2017), indicating that other neuropeptide systems may play a 
critical role in stress-related pathologies. 
 
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) 
PACAP, PACAP receptors, and signaling 
The pituitary adenylate cyclase-activating polypeptide (PACAP) is a 38-amino acid 
peptide belonging to the secretin/glucagon/vasoactive intestinal polypeptide (VIP) 
superfamily (Miyata et al., 1989). PACAP is derived from a 176 amino acid precursor (pre-
pro-PACAP) that is cleaved to PACAP-38, PACAP-27, and PACAP-related protein (PRP) 
through processing by a prohormone convertase (PC) (Ogi et al., 1990). All three peptides 
are present in tissue, with the dominating form being PACAP-38 (Arimura et al., 1991). 
PACAP gene expression is, in part, regulated transcriptionally and post-transcriptionally 
by cyclic AMP (cAMP) and calcium (Ca2+) signals in neurons (Fukuchi et al., 2016). 
PACAP exerts its effects in part via its cognate receptor PAC1 (PAC1R), which 
PACAP binds with an affinity 1000-fold greater compared to VIP. On the other hand, 
PACAP and VIP bind VIP receptors VPAC1 and VPAC2 with equal affinity (Vaudry et 
al., 2009). PAC1R and VPAC1/2 are class B GPCR and therefore contain a seven-
transmembrane domain with extracellular loops that enable ligand binding and intracellular 
protein domains that enable the transduction of signaling cascades. PACAP/PAC1R-




phospholipase C (PLC), through Gq (Vaudry et al., 2009). Activation of the PLC cascade 
results in the cleaved production of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol 
(DAG). DAG production leads to the activation of protein kinase C (PKC) and this, along 
with DAG, increase intracellular calcium (Harmar, 2001). Alternatively, Gs stimulation of 
AC results in activation of protein kinase A (McCulloch et al., 2002). PACAP receptor 
signaling is depicted in Figure 2 [from (Dickinson and Fleetwood-Walker, 1999)]. In 
addition, PAC1R undergoes endocytosis upon ligand binding, to activate neurotrophic 
signaling necessary for cell survival (May et al., 2010); furthermore, PAC1R 
internalization mediates PACAP-induced increases in neuronal excitability through 
vesicular endocytosis and signaling (Merriam et al., 2013). 
In the brain, PACAP and PAC1R are highly expressed in both the hypothalamus 
and the extended amygdala (Joo et al., 2004; Piggins et al., 1996) where they stimulate the 
release and the synthesis of various hypophysiotropic neurohormones including CRF. The 
PACAP/PAC1 system regulates food intake, energy metabolism, body temperature, 





Fig. 2. PACAP/PAC1R signaling. PACAP binding of PAC1R leads to either the 
activation of Gq or Gs proteins, which stimulate phospholipase C (PLC) or adenylate cylase 
(AC), respectively.  The VPAC1 and VPAC2 receptors are both primarily coupled to the 
AC-stimulating Gs. AC stimulates cAMP which results in PKA activation. The Gq-
activated PLC cascade leads to production of inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG), resulting in protein kinase C (PKC) and calcium stimulation. AC 
stimulates cAMP which results in PKA activation. [Diagram from (Dickinson and 




PACAP in psychiatric illnesses 
Recent clinical studies has suggested the involvement of the PACAP/PAC1R 
system in the development and persistence of several psychiatric disorders.  A gene 
association study found a link between MDD and a genetic variant in ADCYAP1, the gene 
that encodes for PACAP, and has shown associations between this locus and schizophrenia 
and bipolar disorder (Hashimoto et al., 2010).   Heavily traumatized females have been 
shown to have PACAP blood levels that positively correlate with the severity of their post-
traumatic stress disorder (PTSD) symptoms.  Additionally a single nucleotide 
polymorphism (SNP) in a putative estrogen response element within the PAC1R gene 
(encoded by ADCYAP1R1) was found to predict PTSD diagnosis and symptoms (Ressler 
et al., 2011).  These findings suggest that perturbations of the PACAP/PAC1R system may 
be involved in the etiopathology of MDD and PTSD.   
 
Role of the PACAP system in anxiety-like and depressive-like behavior 
Preclinical work on PACAP has been investigating its role in modulating the stress 
response.  Early work from our group demonstrated that intracerebroventricular (i.c.v.) 
injections of PACAP are able to increase mRNA levels of the stress peptide CRF in the 
PVN and to increase anxiety-like behavior via CRF receptor activation (Dore et al., 2013).  
Behavioral effects of i.c.v. PACAP result in increased face washing, body grooming, 
rearing, and wet-dog shakes in rats (Agarwal et al., 2005). PACAP i.c.v. infusion has also 
been shown to increase plasma corticosterone levels and, in line with the HPA-modulating 




induced corticosterone secretion (Agarwal et al., 2005; Dore et al., 2013; Stroth and Eiden, 
2010).   
Studies have also begun to investigate the neurocircuitry through which the 
PACAP/PAC1R system exerts its behavioral and neuroendocrine effects. PACAP 
administration directly into the CeA causes a switch in stress-coping behaviors from active 
burying to the passive modes of withdrawal and immobility in the shock-probe fear test 
(Legradi et al., 2007).  Our laboratory has also shown that PACAP microinfusion into the 
CeA, but not the BlA, induces anxiogenic-like effects in multiple behavioral tests and 
elevates plasma corticosterone levels (Iemolo et al., 2016).  In the context of BNST 
signaling, local PACAP microinfusion in the BNST have been shown to also produce 
anxiogenic responses, and PACAP receptor blockade to prevent the endocrine and 
behavioral effects of chronic variable stress (Hammack et al., 2009). Chronic variable 
stress increases mRNA expression of PACAP and PAC1R in the BNST (Hammack et al., 
2009).    
 
Thesis objectives 
This dissertation focuses on the role that the PACAP system of the extended 
amygdala plays in the physiological as well as pathological behavioral response to stress, 
as brought about by either acute or chronic stressors. In my first set of experiments (chapter 
2), I screened for depressant-like effects after the i.c.v. administration of PACAP using 
intracranial self-stimulation (ICSS), saccharin preference, social interaction, and forced 




PACAP administered directly into the CeA or BNST in producing stress-like behavior 
using the acoustic startle test, and I explored whether the endogenous PACAP signaling of 
these brain areas mediates the sensitization of the acoustic startle response induced by an 
acute stressor. Lastly (chapter 4), I used the chronic social defeat model to assess the effects 
of chronic stress on PACAP/PAC1R expression in CeA and BNST and the functional 
relevance of the activation of the PACAP/PAC1R system in the physiological and 
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Major Depressive Disorder (MDD) is a chronic, life-threatening psychiatric 
condition characterized by depressed mood, psychomotor alterations, and a markedly 
diminished interest or pleasure in most activities, known as anhedonia. Available 
pharmacotherapies have limited success and the need for new strategies is clear.  Recent 
studies attribute a major role to the pituitary adenylate cyclase-activating polypeptide 
(PACAP) system in mediating the response to stress. PACAP knockout mice display 
profound alterations in depressive-like behaviors and genetic association studies have 
demonstrated that genetic variants of the PACAP gene are associated with MDD. However, 
the effects of PACAP on depressive-like behaviors in rodents have not yet been 
systematically examined.  
The present study investigated the effects of central administration of PACAP in 
rats on depressive-like behaviors, using well-established animal models that represent 
some of the endophenotypes of depression. We used intracranial self-stimulation (ICSS) 
to assess the brain reward function, saccharin preference test to assess anhedonia, social 
interaction to assess social withdrawal, and forced swim test (FST) to assess behavioral 
despair.  
PACAP raised the current threshold for ICSS, elevation blocked by the PACAP 
antagonist PACAP(6-38). PACAP reduced the preference for a sweet saccharin solution, 
and reduced the time the rats spent interacting with a novel animal. Interestingly, PACAP 




Our results demonstrate a role for the central PACAP/PAC1R system in the 
regulation of depressive-like behaviors, and suggest that hyperactivity of the 
PACAP/PAC1R system may contribute to the pathophysiology of depression, particularly 






Major Depressive Disorder (MDD) is a chronic, life-threatening psychiatric 
condition which affects 16% of the population at some point in their lives in the United 
States (Kessler et al., 2003). MDD is characterized by depressed mood, psychomotor 
alterations as well as a markedly diminished interest or pleasure in most activities, also 
known as anhedonia (American Psychiatric Association, 2013). Despite the persistent work 
on trying to understand the neurobiological substrates of this disorder, there is still much 
to be discovered regarding the circuitry responsible for the different symptoms of MDD.  
Growing evidence attributes a major role to neuropeptide systems in mediating the 
stress response as well as depression and anxiety, making them potential drug targets for 
the treatment of affective disorders (Holmes et al., 2003).  In particular, there is 
accumulating evidence that the pituitary adenylate cyclase-activating polypeptide 
(PACAP) system plays an important role in the behavioral and endocrine responses to 
stress, as well as in synaptic plasticity and neuroprotection (Hammack and May, 2015). 
PACAP is the most conserved peptide of the growth hormone-releasing hormone 
(GHRH)/secretin/glucagon/vasoactive intestinal peptides (VIP) superfamily (Vaudry et al., 
2009). Two fragments of PACAP exist, PACAP-38 and PACAP-27, the former 
representing more than 90% of the total peptide in the brain tissue (Piggins et al., 1996). 
PACAP functions as a neurohormone and neuromodulator through its G protein-coupled 
receptor PAC1, which binds PACAP with much greater affinity than VIP (Kd: 0.5 vs. 4500 
nM) (Harmar et al., 1998). The PACAP/PAC1 system regulates food intake, energy 




PACAP and its receptor PAC1 are highly expressed in several nuclei of the hypothalamus 
as well as in various extra-hypothalamic regions including the amygdala, the hippocampus 
and the nucleus accumbens (Joo et al., 2004; Piggins et al., 1996).  
Administration of PACAP intracerebroventricularly (i.c.v.) as well as into the 
paraventricular nucleus of the hypothalamus (PVN), the central nucleus of the amygdala 
(CeA) and the bed nucleus of the stria terminalis (BNST) has been shown to produce a 
stress-like response and to activate the hypothalamic–pituitary–adrenal (HPA) axis as well 
as extrahypothalamic corticotropin-releasing factor (CRF) systems (Agarwal et al., 2005; 
Dore et al., 2013; Missig et al., 2014; Norrholm et al., 2005). While on one hand PACAP 
knockout mice have been shown to display attenuations in serum corticosterone levels and 
depressive-like behaviors after a chronic stress paradigm (Lehmann et al., 2013), other 
studies have instead described a pro-depressive-like phenotype of PACAP knockout mice, 
which was, however, not reproduced in later studies (Hashimoto et al., 2009; Hattori et al., 
2012).  However, the effects of exogenously administered PACAP on depressive-like 
behaviors have not yet been described.  
In this paper we sought to further characterize the pro-depressive-like effects of 
PACAP using well established animal models of anhedonia and behavioral despair, 
endophenotypes of depression. We used intracranial self-stimulation (ICSS) to assess the 
brain reward function, forced swim test (FST) to assess behavioral despair, saccharin 
preference test to assess anhedonia, and social interaction to assess social avoidance, 





Materials and Methods 
Animals 
Male Wistar rats, weighing 300-325g upon arrival (Charles River, Wilmington, 
MA), were housed in a 12h:12h reverse light cycle (lights off at 11am), humidity and 
temperature-controlled vivarium, with food and water available ad libitum. Animals were 
allowed a minimum of 2 weeks to habituate to the vivarium; all experiments were done 
during the rats’ dark cycle. Procedures adhered to the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals and the Principles of Laboratory Animal Care 




Saccharin solution (0.5% w/v) was prepared using saccharin sodium salt hydrate 
(Sigma–Aldrich) and tap water. PACAP-38 (agonist) (here called PACAP) and PACAP(6-
38) (antagonist) were purchased from the American Peptide Company (Sunnyvale, CA). 
Both peptides were dissolved in sterile isotonic saline in the presence of 1% bovine serum 
albumin (Sigma-Aldrich, St. Louis, MO), and were administered i.c.v. in a volume of 5 
µL, either alone or as a cocktail in a single micro-infusion. PACAP doses were chosen 
based on previous studies showing that similar doses produce anxiogenic and anorectic 
effects lasting up to 3-6 hours (Dore et al., 2013; Mounien et al., 2009; Telegdy and 
Adamik, 2015). PACAP(6-38) doses were chosen also based on previous reports (Burgos 




saccharin preference, social avoidance and forced swim tests, 0 min in the ICSS test (since 
the first 2 columns of the procedure were not used in the analysis, see below).  
 
Intracranial surgery and micro-infusion procedures 
Stereotaxic surgeries were performed as previously described (Iemolo et al., 2012; 
Sabino et al., 2007). Rats were implanted with a 24-gauge stainless steel cannula (Plastics 
One, Roanoke, VA) into the lateral ventricle (from Bregma: AP +1.06 mm, ML ± 0.75 
mm, DV -5.5 mm, flat skull) determined using Paxinos and Watson (2007). For the ICSS 
experiment, the i.c.v. coordinates were adjusted to permit both the cannula and the 
electrode to fit in the same rat (AP: -1.0, ML: -3.2 with 20° tilt, DV: -2.6 from skull, incisor 
bar set 5.0 mm above the interaural line). After surgery, rats were singly housed and 
allowed to recover for at least 5 days before behavioral testing began. For micro-infusions, 
a 31-gauge internal injector with 2.5 mm projection was placed into the guide cannula, 
connected via PE20 tubing to a Hamilton microsyringe driven by a pump (KD Scientifics, 
Holliston, MA). Injections were administered at a rate of 2.5 µL/min and injectors were 
left in situ for an additional minute to prevent backflow.  
 
Intracranial self-stimulation (ICSS) test  
Surgery for electrode implantation and ICSS procedure were performed as 
previously described (Iemolo et al., 2012). Rats were unilaterally implanted with a 0.125-
mm diameter bipolar stainless steel electrode (Plastics One; length ≈10.5 mm) into the 




AP -0.5mm, ML -1.7mm; DV -9.7mm from skull; incisor bar set 5.0mm above the 
interaural line).  
Rats were first trained to lever press on a fixed ratio 1 schedule of reinforcement to 
obtain an electrical stimulation until responding was established. Mean reward thresholds 
for each subject were then assessed for 3-4 weeks before drug infusions started using a 
rate-independent discrete-trial current intensity procedure originally designed by Dr. 
Kornetsky (Kornetsky and Esposito, 1979). Rats were trained to lever press on a fixed ratio 
(FR) 1 schedule of reinforcement to obtain 500-ms trains of electrical stimulation. Once 
stable FR1 operant responding for the electrical stimulus was established, ICSS thresholds 
were assessed using the following procedure (Iemolo et al., 2012; Valenza et al., 2015). At 
the beginning of each trial, rats received a noncontingent stimulus (S1), after which they 
had the opportunity, during a 7.5 s limited period, to lever press, which resulted in the 
delivery of a contingent stimulus (S2) that was identical to the previous S1. A 7.5–22.5 s 
(average 15 s) period of time elapsed between S2 delivery and the delivery of the next S1. 
If no response occurred, this time period began at the end of the 7.5-s period allotted for 
response. These time periods were randomized so that animals could not ‘predict’ the next 
S1 delivery. A‘trial’ consisted of five presentations of S1 at a fixed current intensity (in 
µA). Three or more responses at that intensity were scored as a plus (+) for that trial, 
whereas two or fewer responses were scored as a minus (−) for that trial. If the animal 
scored a (+) for the first trial, the second trial began at an intensity of 5 µA lower than the 
first. The current intensity continued to decrease by the same fixed intensity until the 




the second trial at which a (−) score was obtained was repeated and the current intensities 
were then ascended by 5 µA for each trial until the animal scored a (+) for two consecutive 
trials. Each set of ascending or descending current intensities was defined as a ‘column’, 
and a total of six alternating descending/ascending columns were performed for each 
session. The intensity at the midpoint between (+) and (−) was defined as the column 
threshold. The threshold for each session was calculated as the mean of the last four column 
thresholds; the first and second column thresholds were, therefore, excluded, as they were 
the most unstable. To discourage the subject from responding during the inter-trial interval, 
any response during this period postponed the onset of the S1 for an additional 22.5 s (a 
length of time that exceeded or was equal to the original random duration of the inter-trial 
interval).  
The reward threshold is defined as the minimal current intensity able to produce a 
response that maintains the self-stimulation behavior. An increase in the reward threshold 
indicates that stimulus intensities that were previously perceived as reinforcing are no 
longer perceived as rewarding, reflecting an overall decrease in reward function (Markou 
and Koob, 1992). The response latency is defined as the mean response latency of all trials 
within a session during which a positive response occurred. Rats were trained daily until a 
stable reward threshold was achieved. On drug testing days, animals were injected with 
PACAP (0, 1, 3 µg/rat) immediately before their ICSS test session, in a within-subject, 
latin square design. At least two treatment-free days were allowed between treatment days, 





Saccharin preference test 
On day 1 of the saccharin preference test, rats were presented with 2 water bottles 
for 4 hours in their home cages at dark cycle onset. On day 2, rats received one bottle 
containing water and another containing a 0.5% saccharin solution for 2 hours. The 
saccharin bottle was then exchanged for a water bottle for 2 additional hours. On day 3, 
rats were allowed access to both saccharin and water bottles for 4 hours. Rats were water 
deprived for 20 hours on day 1, 2 and 3 to encourage drinking in a short period of time.  
On day 4, the test day, the drug was administered 30 min before bottle (water and saccharin) 
presentation; water and saccharin consumption were measured by weighing the bottles 
before and at the end of the 4-hr test period.  
 
Social avoidance test 
The social avoidance paradigm in rats was based on the social approach-avoidance 
test previously described in both rats and mice (Lukas et al., 2011). In our study, the test 
was slightly modified. The test took place during the rats’ active phase, under red lights. 
Rats were placed in a novel arena (100 x 100x 40 cm). After 30 s of habituation, an empty 
wire-mesh cage (64 x 32 x 25 cm) was placed at one side wall of the arena for 4 min, during 
which the experimental rat could gain familiarity with the arena and the novel empty cage. 
An unknown male Wistar con-specific (social stimulus) was then inserted into the cage for 
an additional 4 min. The arena was cleaned with quatricide between rats.  The test was 
recorded with a camera and the time the experimental rat spent interacting with the 




Forced Swim Test (FST) 
A one-day protocol was used. 30 min after drug administration rats were placed 
into a clear Acrylic cylinder (25 cm diameter) filled with water (24°C; 42 cm deep) for 
15 min. The test was videotaped and later scored for the time rats spent climbing, 
swimming, and immobile by an experimenter blind to the treatments. Latency to first 
becoming immobile was also recorded. Behaviors were scored as described in (Cryan et 
al., 2005). Animals were considered immobile when performing the minimum movements 
required to keep their head above water, in the absence of other behaviors. Climbing was 
defined as upward-directed movement of the forepaws aimed toward the sides of the 
cylinder. Swimming was defined as horizontal movement throughout the cylinder. At the 
end of the session rats were removed from the cylinder, dried and placed into a 
polycarbonate cage located on a heating pad for 15 min. The rats were finally returned to 
their home cage. 
 
Statistical Analysis 
ICSS dose-response data were analyzed using a repeated measure analysis of 
variance (ANOVA) with Dose as a within-subject factor. ICSS threshold blockade data 
were analyzed using a two-way repeated measure ANOVA with PACAP and Antagonist 
as within-subject factors. Data from the social avoidance, sucrose intake and FST studies 
were analyzed using one-way ANOVAs. Pairwise post-hoc comparisons were made using 
Student Newman-Keuls test; Student’s t-test was used when comparing two groups. 











Central administration of PACAP elevates ICSS threshold 
As shown in Figure 3A, PACAP (0-3 µg/rat, i.c.v.) significantly affected the ICSS 
threshold (F(2,12)= 29.75, p<0.001; significant linear trend, p<0.001). Post-hoc analysis 
showed that the highest dose of PACAP (3 µg) elevated the ICSS reward threshold.  
PACAP did not affect latency to respond, as shown in Figure 3B (F(2,12)= 1.14, n.s.; not 





Fig. 3 Effect of PACAP (0, 1, 3 µg/rat, i.c.v.) on (A) reward threshold and (B) latency 
(n= 7). Data represent Mean ± SEM. *** p < 0.001 vs. vehicle-treated group (Student 








The PAC1R antagonist PACAP(6-38) blocks PACAP-induced elevation of ICSS threshold 
Administration of the selective PAC1R antagonist PACAP(6-38) (0-7.5 µg/rat, 
i.c.v.) did not affect ICSS threshold per se (F(2,18)= 0.93, n.s.; not significant linear trend), 
as shown in Figure 4A. However, when co-administered with PACAP (3 µg/rat, i.c.v.), 
PACAP(6-38) (2.5 µg/rat) blocked PACAP-induced elevation in ICSS threshold (PACAP: 
F(1,6)= 4.68, n.s.; Antagonist: F(1,6)= 0.87, n.s.; PACAP X Antagonist: F(1,6)= 11.88, 
p=0.014), as shown in Figure 4B. Neither PACAP nor PACAP(6-38) affected latency to 





Fig. 4 (A) Effect of selective PAC1 antagonist PACAP(6-38) (0, 2.5, 7.5 µg/rat, i.c.v.) on 
reward threshold (n= 10). (B) Effects of PACAP(6-38) (0, 2.5 µg/rat, i.c.v.) and PACAP 
(0, 3 µg/rat) on reward threshold (n= 7). Data represent Mean ± SEM. * p < 0.05 vs. vehicle-






Central administration of PACAP reduces saccharin intake and preference 
As shown in Figure 5, PACAP (0-3 µg/rat, i.c.v.) significantly affected the intake 
of a saccharin solution (Dose: F(2,20)= 7.26, p<0.01; significant linear trend, p=0.001). 
Post-hoc analysis showed that both doses of PACAP (1 µg and 3 µg) significantly 
decreased 4h saccharin intake (Figure 5A). PACAP did not affect concurrent water intake 
(F(2, 20) = 1.11, n.s.; not significant linear trend), although a not significant trend to 
increase was noticed. PACAP treatment also affected saccharin preference (F(2,20) = 5.77, 
p=0.01; significant linear trend, p<0.01), with the highest dose of PACAP (3 µg) 
significantly decreasing 4-hr saccharin preference, as shown in Figure 5B.  Importantly, 
total fluid intake was not affected by the PACAP treatment (F(2,20) = 2.00, n.s.; not 





Fig. 5 Effect of PACAP (0, 1, 3 µg/rat, i.c.v.) on (A) saccharin intake and water intake 
and (B) saccharin preference (n= 7-8/group). Data represent Mean ± SEM. * p < 0.05; ** 






Central administration of PACAP induces social avoidance 
As shown in Figure 6, PACAP (0-3 µg/rat, i.c.v.) significantly increased social 
avoidance in a social interaction test (F(2, 23)= 7.40, p<0.01; significant linear trend, 
p=0.001). Post-hoc analysis showed that both doses of PACAP (1 µg and 3 µg) 







Fig. 6 Effect of PACAP (0, 1, 3 µg/rat, i.c.v.) on duration of social interaction (n= 8-
9/group). Data represent Mean ± SEM. *p<0.05; **p<0.01 vs. vehicle-treated group 





Central administration of PACAP does not affect immobility time in the FST  
As shown in Figure 7A, PACAP did not significantly affect immobility time in the 
FST (PACAP: F(2,23)= 0.81, n.s.; Time: F(2,46)= 116.33, p<0.001.; PACAP*Time: 
F(4,46)= 0.06, n.s.). However PACAP tended to reduce the latency to first becoming 
immobile, as shown in Fig. 7B (F(2,23)= 2.96, p=0.07; significant linear trend p<0.05). As 
shown in Figure 7C, PACAP did not significantly alter time spent swimming (PACAP: 
F(2,23)= 0.43, n.s.; Time: F(2,46)= 14.44, p<0.001.; PACAP*Time: F(4,46)= 0.98, n.s.) 
or time spent climbing (PACAP: F(2,23)= 1.32, n.s.; Time: F(2,46)= 189.35, p<0.001.; 
PACAP*Time: F(4,46)= 1.19, n.s.).  When the entire 15 min sessions were analyzed 
together, PACAP had still no effect on immobility, swimming or climbing time (see insets 






Fig. 7 Effect of PACAP (0, 1, 3 µg/rat, i.c.v.) on (A) immobility, (B) latency to 
immobility, (C) swimming, and (D) climbing in the FST (n= 8-9/group). Insets represent 






Growing evidence attributes a major role to neuropeptide systems in the mediation 
of the stress response, making them potential drug targets for the treatment of affective 
disorders (for a review see (Holmes et al., 2003)).  The PACAP/PAC1R system has been 
proposed to play a major role in mediating the behavioral and endocrine responses to stress 
(Hammack and May, 2015). Although human and animal studies have suggested the 
possible involvement of the PACAP system in the pathophysiology of anxiety and 
depressive disorders, the effects of exogenously administered PACAP on depressive-like 
behaviors in rodents have not yet been systematically examined.  These series of studies 
comprehensively characterize the effects of PACAP on depressive-like behaviors in the 
rat, using well established animal models of anhedonia, behavioral despair and social 
withdrawal. We demonstrate that central administration of PACAP induces a pro-
depressant phenotype in rats. PACAP administered i.c.v. raised the current threshold for 
ICSS, and this elevation was blocked by co-administration of the PAC1R antagonist 
PACAP(6-38). PACAP reduced the consumption and preference for a sweet saccharin 
solution and reduced the time the rats spent interacting with a novel conspecific animal. 
On the other hand, PACAP administration did not increase immobility in the FST.  The 
results collectively suggest a role for the central PACAP/PAC1R system in the regulation 
of depressive-like behaviors.  
Depression, as in other mental illnesses, consists of endophenotypes which can be 
reproduced independently and evaluated in animals with the goal of identifying novel 




into separate key components that are biologically and clinically meaningful and can be 
assessed quantitatively, called psychopathological endophenotypes (e.g. depressed mood, 
impaired reward function or anhedonia, impaired learning and memory, psychomotor 
alterations, increased stress sensitivity, etc.) (Hasler et al., 2004).  In the present 
investigation we utilized reward-based (ICSS, consumption of sweet solutions), behavioral 
despair (FST), and social withdrawal models to explore the role of the PACAP/PAC1R 
system.  
PACAP-treated rats showed a dose-dependent increase in ICSS threshold, defined 
as the current intensity that supports operant behavior in the discrete-trial current-intensity 
intracranial self-stimulation procedure, confirming previous results obtained with higher 
doses of the peptide (Dore et al., 2013). An increase in ICSS threshold is indicative of a 
decrease of the rewarding properties of the electrical stimulations (i.e. higher currents are 
needed to feel the same pleasure) (Markou and Koob, 1992). A number of conditions 
known to trigger depressive states in humans also cause deficits in the brain reward system 
function of animals as measured by ICSS; this is the case of chronic stress, such as chronic 
variable stress or chronic social defeat (Der-Avakian et al., 2014; Moreau et al., 1995), as 
well as withdrawal from abused drugs, such as ethanol and cocaine and nicotine (Markou 
and Koob, 1991; Schulteis et al., 1995). For this reason increases in ICSS thresholds, 
reflecting deficits in brain reward circuitries, are widely recognized as a sign of 
“anhedonia”, i.e. diminished interest or pleasure in rewarding activities and a core 
symptom of major depression and other affective disorders (American Psychiatric 




antidepressant drugs is able to attenuate raises in ICSS threshold (Markou et al., 1992).  
We also demonstrated that co-infusion of the PAC1R antagonist PACAP(6-38) 
blocked the PACAP-induced elevations of the ICSS thresholds. It is important to note that 
although the well-characterized PACAP(6–38) is used as a PAC1R antagonist in many 
studies, it also exhibits high potency at VPAC2 receptors (Dickinson et al., 1997). The 
finding that PAC1R knockout mice behave as PACAP knockout in the context of stress-
related behaviors (Mustafa et al., 2015), together with the observation that VIP appears to 
have an anxiolytic-like profile (Ivanova et al., 2014) and promote social contact and pair 
bonding (Kingsbury and Goodson, 2014), strongly suggest the exclusive involvement of 
PAC1R in the regulation of mood and social interaction. However, future studies will need 
to test more specific PACAP receptor antagonists as become available in order to evaluate 
the specific role of the individual receptors in the observed effects.  Interestingly, 
PACAP(6-38) had no per se effect on ICSS threshold, suggesting the lack of a tonically 
active PACAP/PAC1 system in baseline, non-aversive condition.  Our results are in line 
with previous results showing a lack of effect of PACAP(6-38) in unstressed animals as 
compared to animals exposed to chronic variable stress (Roman et al., 2014), and are 
reminding of the “normalizing” profile of CRF receptor antagonists on brain stimulation 
reward as well as anxiety-like behavior, which have been shown to affect these behaviors 
exclusively in conditions of high stress or arousal (Heinrichs et al., 1992; Macey et al., 
2000). An alternative explanation for the lack of effect of PACAP(6-38) in ICSS can be 
related to the fact that the behavioral tests in this study were performed during the dark 




Importantly, neither PACAP nor PACAP(6-38) treatment affected the latency to 
start lever pressing, which is considered a measure of operant performance and therefore 
general motor activity in the ICSS procedure (Markou and Koob, 1992). This finding 
excludes potential locomotor suppressive effects of the peptides, in line with a lack of 
increased immobility in the FST as well as previous reports showing no locomotor 
impairment following administration of PACAP in rodents (Dore et al., 2013; Iemolo et 
al., 2015; Kocho-Schellenberg et al., 2014; Mounien et al., 2009; Resch et al., 2011). We 
believe that the demonstration of the attenuation in the brain reward system function 
following administration of PACAP is a very significant one, as ICSS can be considered a 
direct read-out of intact reward functioning in the brain. 
Even though in this study we have not directly measured the effect of PACAP on 
HPA activation, several previous reports have shown that similar doses of PACAP do 
activate the HPA axis (Agarwal et al., 2005; Dore et al., 2013; Norrholm et al., 2005). 
However, considering the rapid effects of PACAP, our data suggest instead an effect of 
PACAP on hedonic behaviors, independently of HPA axis activation.  This hypothesis is 
also supported by the observation that acute administration of steroids has been found to 
either not affect or even increase brain stimulation reward (Barr et al., 2000; Goodwin et 
al., 1992; Slusher, 1965). Moreover, bilateral adrenalectomy has been shown to fail to alter 
self-stimulation thresholds acutely (Abrahamsen and Carr, 1997; Abrahamsen et al., 1997).  
Consequently, it appears that acute activation of the HPA stress system, through the release 
of ACTH and corticosterone, either does not affect or even stimulates rather than inhibit 




the effects of PACAP on ICSS observed in the present study.  
We found that rats treated with PACAP showed a dose-dependent decrease in 
intake of a palatable saccharin solution, which was reduced 49.9% by the highest dose, 
compared to vehicle. Interestingly, a statistically non-significant trend to increased 
concurrent water intake (53.3% by the highest dose, compared to vehicle) was observed, 
which speaks against the alternative hypothesis of general malaise. As a consequence, total 
fluid intake was not significantly affected by the treatment. Chronic stress is known to 
reduce the intake and preference of sweet solutions (as well as water) and chronic treatment 
with antidepressant drugs has been shown to increase sucrose preference as well as 
attenuate the reduction in sucrose consumption by chronic stress (Sampson et al., 1991; 
Willner et al., 1987). Sucrose/saccharin preference shares a common theoretical basis with 
ICSS. Reduced intake and preference for sweet solutions represents the loss of interest, 
fatigue and loss of energy common during depressive episodes. Like ICSS, preference for 
sweet solutions can be a measure of the affective state and motivation of rodents, and thus 
is another putative measure of anhedonia (D'Souza and Markou, 2010). Therefore, we 
demonstrate that central administration of PACAP causes a generalized decrease in 
sensitivity to rewards.  It should be noted, however, that an alternative explanation for the 
reduction of saccharin intake may involve a potential reduction of place preference by 
PACAP, rather than a pure attenuation of the hedonic response; future studies investigating 
the effects of PACAP on place conditioning may help shed light on this question. 
Based on the effects on ICSS and saccharin preference, a pro-depressant effect of 




2009; Morley et al., 1992; Mounien et al., 2009) and this raises the possibility that the 
observed effects could be the result of this. However, saccharin is a non-caloric reinforcer 
(unlike sucrose, reason for which it was chosen in this study) and food deprivation is known 
to potentiate the brain reward function as assessed by ICSS (Carr et al., 2000; Goodall and 
Carey, 1975). These observations suggest that the anti-rewarding effect of PACAP is 
unlikely to be a result of decreased food intake.   
In this series of studies, we also found that central PACAP administration caused a 
dose-dependent decrease in social interaction, i.e. it produced social withdrawal. The social 
interaction/avoidance test is an ethologically relevant model of neophobia, depression and 
anxiety that uses the natural form of social behavior as a dependent variable (File and Seth, 
2003). Although decreases in social interaction are most common in anxiety states, it is 
important to note that social dysfunction represents one of the core symptoms of 
depression-related diseases (Merikangas and Angst, 1995). Other “stress” neuropeptides, 
such as corticotropin-releasing factor and cholecystokinin, have been shown to reduce 
social interaction (Dunn and File, 1987; To and Bagdy, 1999), and chronic stress can also 
dramatically impact social interaction (Becker et al., 2008; Berton et al., 2006; Krishnan et 
al., 2007).  A previous report that mice with a deletion of the PACAP gene show increased 
social interaction and an attenuation of social defeat-induced social withdrawal is in line 
with our results (Hattori et al., 2012; Lehmann et al., 2013).  
Finally, we assessed whether central PACAP administration altered behavior in the 
forced swim test. The FST is based on the observation that animals develop an immobile 




is interpreted as an incapacity or reluctance to maintain effort, rather than a generalized 
hypoactivity (Willner, 1990), and this reluctance correlates with the psychomotor 
impairment shown by depressed patients in tests requiring sustained effort (Weingartner 
and Silberman, 1982). Immobility is, therefore, interpreted as a passive stress-coping 
strategy (behavioral despair) (Detke and Lucki, 1996; Porsolt et al., 1978). We found that 
PACAP at the doses used in this study did not reliably affect immobility, swimming or 
climbing in the FST. Noteworthy, PACAP treatment slightly increased the latency of the 
animals to first become immobile, which would essentially suggest an improved coping 
with stressful stimuli.  Several considerations should be made regarding the FST. 
Originally developed to screen antidepressant medications, the forced swim test has more 
recently been used as a putative assessment of depressive-like behavior. However, its 
validity and reproducibility as a model of “depression” is debated and conflicting findings 
have been reported following chronic stressors (Der-Avakian et al., 2014); therefore 
caution should be exercised to avoid over-extrapolation of the behavioral outcome of the 
FST. It is conceivable that the central PACAP/PAC1R system is not involved in the 
mechanism that allows for the development of passive behavior (immobility), which 
disengages the animal from active forms of coping with stressful stimuli. Interestingly, 
PACAP knockout mice have been reported to show decreased immobility in the FST 
(Hashimoto et al., 2009), effect which may however have been confounded by increased 
motor activity of the mutants.  
As immobility time is typically lowest during the first day of FST and increases on 




using a 1-day protocol to avoid a possible floor effect and therefore maximize the chances 
of observing an increase in immobility following administration of the drug.  However, we 
cannot exclude the possibility that in a 2-day paradigm PACAP could have affected 
immobility time, even though the increase in latency to become immobile observed here 
following PACAP administration would suggest otherwise. 
One limitation of this study is that the PACAP antagonist blockade was performed 
exclusively in the ICSS experiment and not in the social interaction or saccharin preference 
tests, due to the fact that while the ICSS test used a within-subject design (therefore 
minimizing the number of experimental subjects), the remainder of the tests used instead a 
between-subject design. Future studies will need to directly ascertain that the effects of 
PACAP on social withdrawal and saccharin preference are indeed also mediated by 
PAC1R.  
Although the tests used in this study all assess some aspects of depression, they 
measure different behavioral outcomes: ICSS measures the sensitivity of the brain reward 
system (the median forebrain bundle), saccharin preference test measures the motivation 
for natural rewards, social interaction measures social behavior and recognition, and FST 
measures the coping with a potential life-threatening situation. Given the marked 
heterogeneity of the paradigms used, it is likely that the four tests rely on different 
neurobiological substrates and neurotransmitters. Since i.c.v., rather than brain site-specific 
infusions were used in this study, additional studies involving site-specific administration 





Many other stress-responsive systems have been implicated in the etiology and 
pathophysiology of mood disorders, including the kappa opioid receptor (KOR) and the 
corticotropin releasing factor (CRF) systems.  KORs are indeed involved in stress and 
depressive-like behaviors (Knoll and Carlezon, 2010); stress promotes the synthesis and 
release of dynorphin (Chartoff et al., 2009) and KOR activation produces dysphoria, 
decreased brain reward function and pro-depressive-like behaviors both in humans and in 
rodents (Bals-Kubik et al., 1993; Pfeiffer et al., 1986; Todtenkopf et al., 2004). 
Interestingly, PACAP has been shown also to increase CRF transcription (Agarwal et al., 
2005); since a CRF receptor antagonist was shown to be able to prevent the anti-rewarding 
effects of PACAP (Dore et al., 2013) and the CRF system is thought to be upstream of 
KOR (Land et al., 2008), we may speculate that PACAP’s effects may be mediated by the 
initial activation of CRF followed by the activation of the dynorphin/KOR system.  
It’s important to note that the anhedonic effects of acute drug administrations 
cannot obviously be regarded as the same as those of chronic administration of stressors. 
However, since chronic exposure to stress ultimately results in similar behavioral endpoints 
as acute PACAP administration, we hypothesize that chronic stress may lead to a 
recruitment of the PACAP system, which would in turn produce anhedonic behaviors.  A 
limitation of the present study is that it involved the exogenous administration of the 
peptide; subsequent studies will need to assess the role of the endogenous PACAP system 
using animal models of depression and pharmacological antagonists or viral knockdown 
of PACAP and/or PAC1. 




motivation to escape threat (by producing aversion) and thus facilitate behavioral 
responses, prolonged PACAP/PAC1R system activation signaling in response to chronic 
stress may instead lead to the long-lasting changes seen in depression. Together our results 
suggest that the hyperactivity of the PACAP/PAC1R system may contribute to the 
pathophysiology of depression, particularly the anhedonic symptomatology and social 







ROLE OF THE PACAP SYSTEM OF THE EXTENDED AMYGDALA IN THE 
ACOUSTIC STARTLE RESPONSE IN RATS 
 
Mariel P. Seiglie, B.A. 1, 2, Lillian Huang1; Pietro Cottone, Ph.D.1; Valentina Sabino, 
Ph.D. 1 
 
1 Laboratory of Addictive Disorders, Departments of Pharmacology and Psychiatry, 
Boston University School of Medicine, Boston, MA 
2 Graduate Program for Neuroscience, Boston University School of Medicine, Boston, 
MA 
 
M.P.S., P.C. and V.S. planned the experiments; M.P.S. and L.H. carried out the 
experiments; M.P.S., P.C. and V.S. analyzed and interpreted the results; M.P.S. wrote a 







Anxiety-related disorders are the most prevalent mental disorders in the world.  
Following a state of threatened homeostasis (i.e. a stressor), components of the stress 
system maintain equilibrium by mobilizing successful adaptive responses. However, 
dysregulation of these fundamental systems may be key to the pathogenesis of conditions 
involving abnormal responses to stressors. Pituitary adenylate cyclase-activating 
polypeptide (PACAP) is a neuropeptide highly expressed in the extended amygdala, a basal 
forebrain structure involved in the response to threat that includes the central nucleus of 
the amygdala (CeA) and the bed nucleus of the stria terminalis (BNST). In this paper, we 
used the acoustic startle response (ASR), an unconscious response to sudden stimuli 
sensitive to changes in stress which can be used as the primary operationalization of the 
hypervigilance present in anxiety-related disorders. The aim of this series of experiments 
was to systematically elucidate the role of the PACAP system of the CeA and BNST in 
ASR, under both control, unstressed conditions and after the presentation of a stressor, 
which produces startle hyper-reactivity, a common feature of some anxiety disorders.   We 
found that infusion of PACAP, but not the related peptide vasoactive intestinal peptide 
(VIP), into either the CeA or the BNST causes a dose-dependent increase in ASR. In 
addition, while infusion of the PACAP antagonist PACAP(6-38) into either the CeA or the 
BNST does not affect ASR in non-stressed conditions, it prevents the sensitization of ASR 
induced by footshock stress. Finally, we found that footshock stress induces a significant 
increase in PACAP, but not VIP, levels in both of these brain areas. Altogether, these data 











Anxiety disorders are a massive public health issue which costs $42 billion a year 
and affects approximately 40 million Americans (Greenberg et al., 1999; Kessler et al., 
2005). Symptoms of anxiety disorders include excessive fear of a stimulus or perceived 
threat which can manifest with hypervigilance and hyperarousal. All the components of the 
stress systems respond to states of threatened homeostasis (i.e. presentation of a stressor) 
by mobilizing adaptive responses aimed to maintain the equilibrium. However, 
hyperactivation of these fundamental arousal and emotional systems may be key to the 
pathogenesis of conditions involving abnormal responses to stressors.    
A behavioral test that has proven very useful in the investigation of the neural 
mechanisms of hypervigilance very common in anxiety disorders is the acoustic startle 
response (ASR). The ASR is a rapid reflex to an abrupt auditory stimulus that is mediated 
by very well defined neuronal pathways in the cochlear nucleus of the brainstem and spinal 
cord (Lee et al., 1996). The response to the stimuli consists in the rapid contraction of the 
facial and skeletal muscles, and it is conserved in both animals and humans. Patients with 
posttraumatic stress disorder (PTSD) exhibit an exaggerated ASR (Butler et al., 1990; 
Grillon et al., 1998; Morgan et al., 1996). In rats, ASR has been proven to be a dependable 
measure of current emotional state, and alterations in baseline ASR are routinely used to 
determine anxiety level (Davis, 1993; Davis et al., 2010). Another advantage of using ASR 
is that it has a nonzero baseline, which allows bidirectional changes to be detected (Gerber 
et al., 2014). It has been shown that ASR can be increased as an unconditioned effect of an 




(Davis, 1989); this sensitization is also observed following various chronic stress 
paradigms (Gewirtz et al., 1998; Hammack et al., 2009), and it is likely to reflect a 
heightened state of anxiety as a result of the stress exposure.  
In the context of stress and anxiety, two major structures are known to modulate 
changes in ASR, the central nucleus of the amygdala (CeA) and bed nucleus of the stria 
terminalis (BNST) (Davis et al., 1997).  These brain regions are both part of the extended 
amygdala, an anatomical construct which regulates the emotional component of the stress 
response (Koob and Le Moal, 2005). The CeA integrates sensory information from the 
environment, and sends projections to the BNST (Alheid et al., 1998; Alheid and Heimer, 
1988). In addition, both structures project this information to various effector regions, such 
as the hypothalamus, the cortex, and the brainstem, to trigger the appropriate responses, 
therefore coordinating the behavioral, autonomic and endocrine response to threat (Davis, 
1992; Davis and Shi, 2000; Pitkanen et al., 2000; Zarrindast et al., 2008). Notably, while 
in a non-pathological state, extended amygdala signaling is tapered appropriately to the 
severity of the present threat (Mathew et al., 2008), hyperactivity stemming from the 
extended amygdala is hypothesized to play a critical role in the pathophysiology of anxiety 
and depressive disorders, which are characterized by exaggerated stress responses to stress 
(Etkin et al., 2009; Etkin and Wager, 2007; Shin and Liberzon, 2010).  
The CeA and BNST are anatomically similar in regards to cell types and 
neurochemical makeup, especially with respect to the presence of several important 
neuropeptides. A neuropeptide system growing in popularity is the pituitary adenylate 




secretin/glucagon/vasoactive intestinal polypeptide (VIP) superfamily. PACAP exerts its 
effects mainly via its cognate receptor PAC1 (PAC1R), which binds PACAP with an 
affinity of 1000-fold greater than VIP. VIP receptors (VPAC1R and VPAC2R), on the 
other hand, bind PACAP and VIP with equal affinities (Vaudry et al., 2009).  In the brain, 
PACAP and PAC1R are highly expressed in the hypothalamus, the brainstem, and the 
extended amygdala (Joo et al., 2004; Piggins et al., 1996). Unfortunately, very few 
selective ligands are available for PAC1R (Laburthe et al., 2007). Dense PACAP-
immunoreactive fibers are found in the dorsolateral BNST and in the capsular and lateral 
parts of the CeA subdivision (Hannibal, 2002; Piggins et al., 1996). It is important to note 
that in these areas PACAP-immunoreactive fibers significantly outnumber PACAP-
positive soma, suggesting that the PACAP fibers are coming from non-local projections to 
the CeA and BNST.  
In an important human study, a single nucleotide polymorphism in a putative 
oestrogen response element within the PAC1R gene was shown to predict PTSD symptom 
severity in highly traumatized females (Ressler et al., 2011), suggesting a possible key role 
of the PACAP system in PTSD. Recent preclinical literature has also implicated PACAP 
as a strong mediator of the stress response. Knockout mice studies have proven that several 
effects of stress, like HPA-axis activation and anxiety-like behavior, are dependent on 
PACAP signaling (Hashimoto et al., 2001; Lehmann et al., 2013; Stroth and Eiden, 2010). 
Central administration of PACAP to rodents evokes a stress-like response, activates the 
HPA axis, and induces depressive-like behavior (Agarwal et al., 2005; Dore et al., 2013; 




microinfusion into the CeA produces anxiety-like behavior in the EPM and defensive 
withdrawal test (Iemolo et al., 2016; Missig et al., 2014) as well as increased passive-
coping in the shock-probe fear test (Legradi et al., 2007). PACAP microinfusions into the 
BNST also increase anxiety-like behavior in the EPM and increase acoustic startle 
reactivity (Hammack et al., 2009; Roman et al., 2014). 
The aim of the present study was to systematically elucidate the role of the PACAP 
system of the CeA and the BNST in in ASR, under both unstressed conditions and after 





Materials and Methods 
Subjects 
Adult, male Wistar rats (Charles River, Wilmington, MA) weighing 301-325g upon 
arrival were single-housed in wire-topped, plastic cages in a 12h:12h reverse light cycle, 
humidity- and temperature-controlled vivarium, with food and water available ad libitum. 
Experimental tests were conducted during the rats’ dark cycle. Procedures adhered to the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals and the 
Principles of Laboratory Animal Care and were approved by Boston University Medical 
Campus Institutional Animal Care and Use Committee.  
 
Drugs 
PACAP-38 (here referred to as “PACAP”), PACAP(6-38) and VIP-28 (here 
referred to as “VIP”) were purchased from Bachem Americas, Inc. (Torrance, CA); doses 
were calculated based on the salt weights. Peptides were dissolved in sterile isotonic saline 
in the presence of 1% bovine serum albumin (Thermo Fisher Scientific, Waltham, MA) in 
order to prevent peptide degradation and fulfil the requirements for an optimum particulate 
carrier system (Almeida and Souto, 2007). Drugs were administered 30 min prior to the 
startle session in all experiments except the sensitization to startle experiments, where 
PACAP(6-38) was administered 5 min after a pre-shock startle session, i.e. 30 min prior to 
the footshock session, with animals maintained in the home cage for 35 min total. PACAP-




(Iemolo et al., 2016; Missig et al., 2014) . PACAP(6-38) doses were also chosen based on 
previous studies (Grinevich et al., 1997; Roman et al., 2014; Seiglie et al., 2015; Telegdy 
and Kokavszky, 2000). VIP doses matched those of PACAP on a weight basis; being VIP’s 
molecular weight lower than PACAP’s one, this ensured that VIP molar doses were no 
lower than those of PACAP.  
 
Acoustic Startle Response (ASR)  
Acoustic startle response (ASR) experiments were performed using the SR-Lab 
startle response system (San Diego Instruments, San Diego, CA), which consists of a 
Plexiglas cylinder (3.5” internal diameter) resting on a Plexiglas stand placed in a 
ventilated and sound-attenuated plywood chamber. Stimuli were delivered by a speaker 
located 24 cm above the cylinder; startle magnitude was detected in 200 ms bins and 
recorded by a piezoelectric device located beneath the cylinder. Rats were placed in the 
acoustic startle chamber and given 5 min of habituation with white noise only (65dB) prior 
to the start of the session. An ASR session included 30 noise bursts, 50-msec in duration 
(10 each at 95dB, 105dB, and 115dB), which were randomly presented with an average 
inter-trial interval of 30 sec (range of 5-39 sec).  
 
Footshock-Sensitized Acoustic Startle Response (ASR) 
The sensitization protocol, adapted from (Davis, 1989) involved a first ASR session 




trial interval of 30 sec. 5 min after this first, “pre-shock” session, rats were infused 
PACAP(6-38) and placed back in their home cages. 30 min later, rats were returned to the 
startle chamber with a grid floor attached to the animal shocker controller that delivered a 
constant current to the grid. The “post-shock” ASR session, identical to the pre-shock one, 
was preceded by 10 footshock (500-msec in duration, 0.5 mA intensity, 1 per sec). 
 
Intracranial surgeries and microinfusion procedure 
Intracranial surgeries: Rats were stereotaxically implanted with bilateral cannulas 
as described previously (Cottone et al., 2007; Iemolo et al., 2016; Seiglie et al., 2015). 
Briefly, stainless steel, guide cannulas (24 gauge, Plastics One, Inc., Roanoke, VA) were 
lowered either 2.0 mm above the CeA or 1.5 mm above the BNST. Four stainless steel 
screws were fastened to the rats’ skull around the cannulas with the help of dental 
restorative filled resin (Henry Schein Inc., Melville, NY) and acrylic cement. The cannula 
coordinates from bregma used for the CeA were: AP -2.64, ML ±4.2, DV -6.4 (from skull); 
the cannula coordinates used for the BNST were: AP 0, ML ±3.15 at a 14º angle, DV -5.1 
(from skull). The incisor bar set at -3.3 mm below the interaural line. Coordinates were 
chosen according to Paxinos and Watson (Paxinos and Watson, 2007). After surgery, rats 
were allowed a minimum of 7 days of recovery.  
Microinfusion procedure: Drugs were microinfused as previously described 
(Cottone et al., 2007; Iemolo et al., 2016; Seiglie et al., 2015).  A 31-gauge internal injector 




microsyringe driven by a pump (KD Scientifics, Holliston, MA), was placed into the guide 
cannula. Injections were administered at a rate of 0.5 µl/min (total volume: 0.5 µl/side) and 
injectors were left inside for an additional minute to prevent backflow.  
Cannula placement: Cannula placement was verified at the end of all testing. 
Subjects were euthanized under isoflurane anesthesia and injected with 0.5 µl/side of India 
ink. Brains were removed, flash frozen in a methyl butane/dry ice bath and stored at -80˚C. 
Coronal sections of 30 µm were collected using a cryostat and placements verified under a 
microscope. Only subjects with correct placements were included in the analyses.  
 
Immunohistochemistry 
Perfusion and immunohistochemistry: Rats were placed in the startle apparatus and 
exposed to either 10 min of white noise or to a session of footshocks (30 footshock, 500-
msec in duration, 0.5 mA intensity, presented randomly with an average inter-trial interval 
of 30 sec -range of 5-39 sec-). 10 min after the session, rats were anesthetized and then 
transcardially perfused as previously described (Iemolo et al., 2013).  
For PACAP and VIP visualization, brains were cut into 30 µm coronal sections 
using a cryostat and stored in a cryoprotectant solution at −20 °C. Every fourth section 
section (120 µm apart) of the entire BNST and every sixth section (180 µm apart) of the 
entire CeA were chosen randomly and processed for immunohistochemistry. Free-floating 
sections were washed in tris-buffered saline (TBS) between every incubation. For PACAP 




6.0) for 30 min at 80 °C. Sections were placed for 1 hr in blocking solution (3% normal 
goat serum, 0.4% Triton X-100) and subsequently incubated overnight at room temperature 
with primary antibodies against either PACAP (1:500 dilution, T-4473, Peninsula Labs, 
San Carlos, CA) or VIP (1:1,000 dilution, cat # 20077, Immunostar, Hudson, WI) in 
blocking solution. Then, sections were incubated into a secondary antibody (1:400 dilution, 
Alexa Fluor 555 goat anti-rabbit, A-21429, Invitrogen) in blocking solution for 2 hr at room 
temperature. Sections were mounted onto uncoated glass slides and coverslipped with 
Vectashield mounting medium (Vector Laboratories, Burlingame, CA). 
Densitometry: Using the Stereo Investigator software (MicroBrightField, 
Williston, VT), 10X objective pictures of sections containing either the CeA or BNST were 
taken with an Olympus BX-51 microscope equipped with a Rotiga 2000R live video 
camera (QImaging, Surrey, BC), a three-axis MAC6000 XYZ motorized stage (Ludl 
Electronics, Hawthorne, NY), and a personal computer workstation. All pictures were 
captured under a preset exposure and gain in order to standardize the images. Densitometry 
analysis was performed using ImageJ software (NIH) where images were converted to 8-
bit and adjusted using the auto threshold Triangle algorithm. Once converted, mean density 
of immunohistochemical signal was calculated. 
 
Statistical Analysis 
PACAP, PACAP(6-38), and VIP dose-response startle data for CeA and BNST 




intensity as within-subject factors. Pairwise post hoc comparisons were made using 
Newman-Keuls test; Student’s t-test was used when comparing two groups. Significance 







PACAP, but not VIP, administered into the CeA increases ASR 
As shown in Fig. 8A, PACAP microinfusion into the CeA significantly affected 
ASR (Dose: F(2, 20) = 3.63 p <0.05); post hoc analysis showed that both the 0.1 and the 0.3 
µg/rat dose were effective at increasing ASR across noise intensities. Shown in Fig. 8B, 
PACAP significantly increased ASR when noise intensities are collapsed (Dose: F(2, 64) = 
9.04 p <0.05); post hoc analysis showed that both the 0.1 and the 0.3 µg/rat dose were 
effective at increasing ASR. 
On the other hand, as shown in Fig. 8C, VIP microinfusion into the CeA had no 
effect on ASR at any of the doses tested (Dose: F(2, 16) = 0.47, not significant (n.s.)). Shown 
in Fig. 8D, VIP had no effect on ASR when noise intensities are collapsed (Dose: F(2, 52) = 





Fig. 8 Effects of bilateral microinfusion of either PACAP (0, 0.1, 0.3 µg/rat) (A, B) or VIP 
(0, 0.1, 0.3 µg/rat) (C, D) into the CeA of rats on ASR amplitude at increasing noise 
intensities. (B) and (D) show the effects of either PACAP or VIP, respectively, on all noise 
intensities cumulated. N= 11 and 9 (PACAP and VIP, respectively). Bars represent Mean 





PACAP, but not VIP, administered into the BNST increases ASR 
PACAP microinfusion into the BNST significantly affected ASR, as shown in Fig. 
9A (Dose: F(3, 27) = 6.57 p =0.002).  Post hoc analysis showed that the 0.1 and 0.3 µg/rat 
doses significantly increased ASR across the various noise intensities. Shown in Fig. 9B, 
PACAP significantly increased ASR when noise intensities are collapsed (Dose: F(3, 87) = 
14.26 p <0.05); post hoc analysis showed that both the 0.1 and the 0.3 µg/rat dose were 
effective at increasing ASR. 
In contrast, Fig. 9C shows that VIP microinfusion into the BNST had no effect on 
ASR at any of the doses tested (F(2, 12) = 0.72, n.s.). Shown in Fig. 9D, VIP had no effect 





Fig. 9 Effects of bilateral microinfusion of either PACAP (0, 0.03, 0.1, 0.3 µg/rat) (A, B) 
or VIP (0, 0.03, 0.1, 0.3 µg/rat) (C, D) into the BNST of rats on ASR amplitude at 
increasing noise intensities. (B) and (D) show the effects of either PACAP or VIP, 
respectively, on all noise intensities cumulated. N= 10 and 7 (PACAP and VIP, 






The PAC1R/VPAC2R antagonist PACAP(6-38) administered into the CeA blocks 
footshock-induced sensitization of ASR 
ASR was not affected by administration of PACAP(6-38) into the CeA at any of 
the doses tested, as shown in Fig. 10A (Dose: F (2, 24) = 0.57, n.s.).  
Following footshock, vehicle-treated animals showed a 87.1% increase in ASR 
compared to their pre-shock levels (t(9) = -3.22, p <0.05). Animals treated with PACAP(6-
38) (3 µg/rat) did not demonstrate an increase in ASR compared to their pre-shock levels 
(t(6) = -0.22, n.s.). Intra-CeA microinfusion of PACAP(6-38) (3 µg/rat) significantly 
blocked footshock-induced sensitization of ASR compared to vehicle treatment, as shown 





Fig. 10 Effects of bilateral microinfusion of the PAC1/VPAC2 receptor antagonist 
PACAP(6-38) (0, 1, 3 µg/rat) into the CeA of rats on ASR amplitude at increasing noise 
intensities (A), and on ASR amplitude change from pre-shock ASR, i.e. footshock-
sensitized ASR (3 µg/rat) (B).  N= 13 (ASR) and N= 7-10/group (sensitization). Bars 




The PAC1R/VPAC2R antagonist PACAP(6-38) administered into the BNST blocks 
footshock-induced sensitization of acoustic startle 
ASR was not effected by administration of PACAP(6-38) into the BNST, as shown 
in Fig. 11A (Dose: F (2, 18) = 1.51, n.s.).    
Vehicle-treated animals increased their ASR following footshock by 57.8% 
compared to the pre-shock ASR (t(11) = -2.63, p <0.05). Animals treated with PACAP(6-
38) (1 µg/rat) did not show an increase in ASR after exposure to footshock compared to 
their pre-shock startle (t(10) = 0.82, n.s.). Microinfusion of PACAP(6-38) (1 µg/rat) into 
the BNST significantly blocked footshock-induced sensitization of ASR compared to 





Fig. 11 Effects of bilateral microinfusion of the PAC1/VPAC2 receptor antagonist 
PACAP(6-38) (0, 1, 3 µg/rat) into the BNST of rats on ASR amplitude at increasing noise 
intensities (A), and on ASR amplitude change from pre-shock ASR, i.e. footshock-
sensitized ASR (1 µg/rat) (B).  N= 10 (ASR) and N= 11-12/group (sensitization). Bars 





Footshock stress increases PACAP, but not VIP, expression in both the CeA and the BNST 
As shown in Fig. 12A, densitometry analysis performed after 
immunohistochemistry revealed that footshock stress significantly affected PACAP levels 
in the CeA (t(18) = -2.25, p <0.05). Animals exposed to footshock showed a 39.8% 
increase in CeA PACAP density, compared to control, non-footshock animals.  
In contrast, as shown in Fig. 12B, VIP levels in the CeA were not significantly 





Fig. 12 Effects of footshock stress on CeA levels of PACAP (A) and VIP (B).  N= 20 





Footshock stress increases PACAP, but not VIP, expression in the BNST 
As shown in Fig. 13A, densitometry analysis performed after 
immunohistochemistry revealed that footshock treatment significantly affected PACAP 
levels in the BNST (t(17) = -4.72, p <0.001). BNST PACAP showed a 40.1% increase in 
footshock animals, as compared to non-shocked controls.  
On the other hand, footshock had no effect on VIP levels in the BNST, as shown in 





Fig. 13 Effects of footshock stress on BNST PACAP expression (A) and VIP expression 






The main findings of the present study were as follows: (i) PACAP microinfusion 
into either the CeA or the BNST increased ASR in rats; (ii) microinfusion of the related 
peptide VIP in the same brains regions, on the other hand, had no effect on ASR; (iii) 
microinfusion of the PAC1R/VPAC2R antagonist PACAP(6-38) into either the CeA or the 
BNST had no per se effect on baseline ASR, while it blocked footshock-induced 
sensitization of ASR when administered prior to the footshock; (iv) Footshock stress 
increases PACAP levels in both the CeA and BNST, while not altering VIP levels in either 
region. 
Rats microinfused with PACAP into the CeA showed a dose-dependent increase in 
ASR compared to vehicle-treated rats at various noise intensity levels.  This suggests that 
the PACAP drug treatment produces a stress-like effect in the CeA. The highest dose of 
0.3 µg/rat was the most effective at increasing startle compared to vehicle-treated rats 
(134.9%). The finding of a stress-like effect of intra-CeA PACAP in the ASR paradigm is 
novel, but in line with previous studies showing that similar doses of PACAP are able to 
reduce exploration of the open arms of an elevated plus maze (Iemolo et al., 2016).  
Another study has also previously reported an anxiogenic effect of intra-CeA PACAP in 
the same behavioral paradigm, although at significantly higher doses (2 µg/rat) (Missig et 
al., 2014).  
Rats microinfused with PACAP into the BNST also displayed a dose-dependent 
increase in ASR compared to vehicle-treated rats at different noise intensity levels, 




0.3 µg/rat dose was the most effective at increasing ASR (154.3% compared to vehicle). 
These findings confirm previous studies  showing that intra-BNST PACAP increases ASR, 
while expanding them with a full dose-response curve and showing an effect at a 
significantly lower dose than the one previously reported (Hammack et al., 2009; King et 
al., 2017). However, previous studies mentioned did not randomize inter-trial intervals and 
used a maximum noise burst of 105dB.  Notably, microinfusion of the same doses of VIP 
into either the CeA or the BNST was unable to elicit any changes in ASR.  
Pretreatment with the antagonist PACAP(6-38) into either the CeA or the BNST 
did not have an effect on ASR at any of the doses tested. The doses of PACAP(6-38) chosen 
were based on the fact that the IC50 of PACAP(6-38) is 10 times higher than the IC50 of 
PACAP (Robberecht et al., 1992).  These results suggest that inhibiting PACAP signaling 
of the CeA and the BNST under basal, non-stressed conditions does not result in a reduction 
of stress states. 
When ASR is sensitized by a train of footshock, animals show an ASR increase, in 
our case 87% and 58% from their unstressed ASR in the CeA and BNST group, 
respectively. This sensitization of ASR is thought to reflect a rapid unconditioned response 
to a fear-provoking stimulus and to provides a model for a heightened state of anxiety or 
fear (Davis, 1989). Interestingly, the administration of the PAC1/VPAC2 antagonist 
PACAP(6-38) into either the CeA or BNST prior to the footshock stress was able in both 
cases to significantly prevent the development of the ASR sensitization; indeed PACAP(6-





Although the commonly used PACAP(6–38) is used as a selective PAC1R 
antagonist in many studies, it should be noted that it exhibits high affinity also at VPAC2Rs 
(Dickinson et al., 1997; Harmar et al., 1998). However, the efficacy of PACAP(6-38) 
together with the total lack of in vivo effects of VIP in the paradigms used strongly suggests 
that PAC1R, and not VIP receptors, exclusively mediates the anxiogenic effects of 
PACAP.  Indeed, PAC1R selectively binds PACAP with 1000-fold greater affinity than 
VIP, whereas VIP receptors VPAC1R and VPAC2R bind VIP and PACAP with equal 
affinity (Harmar et al., 1998; Shivers et al., 1991). However, future studies utilizing highly 
selective PAC1R agonists and antagonists will be needed to completely rule out a potential 
involvement of receptors other than PAC1R in the effects observed; unfortunately now 
such pharmacological tools are unavailable.   
These results also suggest that endogenous PACAP is not released in these 
extrahypothalamic brain areas under basal, unstressed condition, and that instead this 
system becomes activated in response to a high-intensity, uncontrollable stress. These 
properties make PACAP an attractive therapeutic target, as it would ensure higher safety 
and tolerability in humans.  Other classes of drugs as, for example, benzodiazepines and 
azapirones have been shown to selectively reduce fear- or anxiety-enhanced ASR, while 
not reducing baseline ASR (Hijzen et al., 1995; Walker and Davis, 1997a).  In addition, a 
profile similar to PACAP(6-38) is shared also by corticotropin-releasing factor (CRF) 
receptor antagonists, which show efficacy in exploration-based models of anxiety under 
stressed, but not in non-stressed, testing conditions, suggesting that the activation of stress 




Griebel et al., 2002; Lelas et al., 2004; Okuyama et al., 1999; Zorrilla and Koob, 2010; 
Zorrilla et al., 2002).  
Much work has been done to attempt to characterize the specific function of the 
CeA and BNST in terms of fear and anxiety responses. Lesions of the CeA, but not BNST 
(Hitchcock and Davis, 1991), block expression of fear-potentiated startle using either 
visual or auditory conditioned stimuli (Campeau and Davis, 1995; Hitchcock and Davis, 
1986). These findings implicate the CeA in fear responses while the BNST appears not 
necessary for enhanced fear responses evoked by explicit shock-predicting cues. I.c.v. CRF 
infusions are able to potentiate startle responses (CRF-enhanced startle) (Swerdlow et al., 
1986), and excitotoxic lesions of the BNST, but not CeA completely block this enhanced 
startle (Lee and Davis, 1997). Similarly to CRF-enhanced startle, light-enhanced startle, 
require the BNST but not CeA for its expression (Walker and Davis, 1997b).  
Unfortunately, there remains some uncertainty on how the CeA and BNST differ in these 
types of responses. Specifically, the two hypotheses for these differences are that either the 
CeA plays a role in mediating conditioned fear responses and the BNST unconditioned 
responses or, alternatively, that the CeA plays a role in mediating short-duration fear 
responses and the BNST longer-duration responses (Walker et al., 2009). Interestingly, the 
Davis’ group has demonstrated different ways in which footshock-sensitized startle can be 
blocked by both lesions of the CeA (Hitchcock et al., 1989) and BNST (Davis and Walker, 
2014), therefore our startle sensitization protocol may involve the recruitment of both brain 
regions.  Additionally, lesion studies dissociate all efferent signals from the location of 




strengthen the effects of startle and exaggerate the antagonism at the PAC1R.  
Our pharmacological findings were supported by immunohistochemical results. 
We found that exposure to footshock stress was able to increase PACAP levels in both the 
CeA and BNST of rats.  In contrast, VIP levels were found not to be altered in either brain 
area.  Such elevation in PACAP levels, therefore, is likely responsible for the ASR 
sensitization that occurs following footshock, as confirmed by the observation that 
PACAP(6-38) administration in CeA and BNST was able to prevent its expression. We do 
acknowledge that endogenous release of PACAP within the CeA and BNST may originate 
from outside sources. Even though low to moderate levels of PACAP mRNA have been 
detected in both the BNST (Hammack et al., 2009) and the CeA (personal observations) of 
rats, PACAP neurons originating from the lateral PBn innervate the CeA and BNST and 
are thought to represent a critical source of the peptide, as PACAP immunoreactivity in 
these areas is significantly diminished (60-70%) after PBn lesions (Missig et al., 2014).  
Our data suggest that PACAP is released in extrahypothalamic brain regions, and 
in particular the extended amygdala, following exposure to uncontrollable stressors and 
that, via PAC1R, it mediates the resulting behavioral response of the organism.  We also 
speculate that either a hypersecretion of PACAP or a hyperactivity of PAC1R in the same 
brain areas may occur in certain stress- and trauma-related psychiatric disorders and be 
responsible for some of the behavioral aspects of such conditions, although more 
experimental evidence will be needed to confirm this hypothesis. Our findings suggest 
that pharmacological blockade of PACAP signaling via PAC1R may represent a potential 






THE PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE 
(PACAP)/PAC1 RECEPTOR SYSTEM OF THE CENTRAL AMYGDALA 
MEDIATE THE BEHAVIORAL OUTCOMES OF CHRONIC SOCIAL DEFEAT 
STRESS IN RATS 
 
Mariel P. Seiglie, B.A.1, 2, Clara Velázquez-Sanchez, Ph.D. 1, Pietro Cottone, Ph.D. 1 and 
Valentina Sabino, Ph.D. 1 
 
1 Laboratory of Addictive Disorders, Departments of Pharmacology and Psychiatry, 
Boston University School of Medicine, Boston, MA 
2 Graduate Program for Neuroscience, Boston University School of Medicine, Boston, 
MA 
 
M.P.S., P.C. and V.S. planned the experiments; M.P.S. and C.V.S. carried out the 
experiments; M.P.S., P.C., and V.S. analyzed and interpreted the results; M.P.S. wrote a 






Multiple psychiatric diseases, including anxiety, depressive, and trauma-related 
disorders, stem from an individual’s inability to cope with stressful events; indeed, 
susceptible individuals adapt poorly to stress and end up developing psychopathologies. 
Stress neuropeptides in the extended amygdala circuitry are thought to mediate the 
behavioral response to stress, and dysfunctions of these systems are common to a variety 
of conditions involving a pathological response to stress. Pituitary adenylate cyclase-
activating polypeptide (PACAP) and its receptor PAC1R are highly expressed the central 
amygdala (CeA) and have been proposed to play a role in the behavioral response to stress. 
Here we used chronic social defeat, a clinically relevant rodent model of psychosocial 
stress that produces robust maladaptive behaviors in rodents. We found that chronic social 
defeat stress produced a significant increase in PACAP levels in the CeA of rats, but not in 
the bed nucleus of the stria terminalis (BNST). Suggesting a functional role of this increase, 
PAC1R viral knockdown in the CeA significantly attenuated the reduction in body weight 
gain, anhedonic-like behavior, and increased anxiety-like behavior induced by daily 
chronic social defeat stress, while it had no effects on control, unstressed animals. Finally, 
PAC1R knockdown in the CeA prevented the chronic social defeat stress-induced elevation 
in corticotropin-releasing factor (CRF) levels.  Our data strongly suggest that the 
dysregulation of the PACAP/PAC1R system of the CeA mediates the behavioral outcomes 





Mental disorders are an enormous global health issue due to their high cost to 
society, estimated at $201 billion (Roehrig, 2016), as well as their prevalence. In particular, 
anxiety and depressive disorders represent the heaviest load, accounting for ~55% of all 
disability-adjusted life years due to mental and substance use disorders (Whiteford et al., 
2013).  In addition, 19.1% of U.S. adults have had any anxiety disorder in the past year, 
while 6.7% a major depressive episode, making them the most prevalent mental illnesses.   
Furthermore, the high rate of comorbidity between these disorders is associated with an 
increased rate of psychiatric hospitalization (Kessler et al., 1998) and suicide attempts 
(Devane et al., 2005; Regier et al., 1998; Roy-Byrne et al., 2000).  Many psychiatric 
diseases are thought to stem from an individual’s inability to cope with stressful or 
traumatic events (de Kloet et al., 2005); indeed, susceptible individuals adapt poorly to 
stress and go on to develop psychopathologies including major depressive disorder (MDD), 
as well as anxiety disorders such as post-traumatic stress disorder (PTSD) and panic 
disorder (Juster et al., 2010; Russo et al., 2012). The neurobiological mechanisms 
underlying the pathological response to stress remain poorly understood. 
In this context, the use of animal models pertinent to the human condition is 
necessary. The chronic social defeat stress model (also called “resident-intruder”) is a 
clinically relevant rodent model of psychosocial stress based on chronic social 
subordination that produces robust maladaptive behaviors. Because of its high face validity 
and translational value, this model is well suited to unravel the mechanisms underlying the 




Indeed, defeated animals show a wide range of depressive-like and anxiety-like behaviors, 
as well as physiological changes including decreased body weight gain, all of which are 
normalized by chronic antidepressant treatment (Berton et al., 2006; Krishnan et al., 2007).  
Neuropeptide systems mediating the central response during exposure to stress 
have become increasingly important targets for the understanding of adaptive and 
maladaptive changes to the stress response.  One such neuropeptide that has generated 
significant interest in the recent years is the pituitary adenylate cyclase-activating 
polypeptide (PACAP). PACAP belongs to the GHRH/secretin/glucagon/VIP superfamily, 
and it acts as a neurohormone and neurotransmitter through its G protein-coupled receptor 
PAC1R, which binds PACAP with much greater affinity than the vasoactive intestinal 
peptide (VIP) (Harmar et al., 1998; Vaudry et al., 2009).  Recent literature has implicated 
the PACAP system in the behavioral response to stress. In humans, a single nucleotide 
polymorphism in the PAC1R gene were associated with PTSD symptoms in highly 
traumatized females (Ressler et al., 2011), and a genetic variant in the PACAP gene was 
shown to be associated with MDD (Hashimoto et al., 2010). In rodents, central 
administration of PACAP evokes a stress-like response in rodents, which includes both 
anxiety- and depressive-like symptoms (Agarwal et al., 2005; Dore et al., 2013; Seiglie et 
al., 2015; Stroth et al., 2011). PACAP knockout mice studies display decreased anxiety-
like behavior, as well as attenuated endocrine and behavioral responses after chronic stress  
(Gaszner et al., 2012; Hashimoto et al., 2001; Lehmann et al., 2013; Stroth and Eiden, 
2010) .  Furthermore, exposure to various stressors has been shown to increase 




a few studies have suggested that the central nucleus of the amygdala (CeA) may be a key 
brain site for the actions of PACAP (Dore et al., 2013; Iemolo et al., 2016; Missig et al., 
2014).  The CeA integrates sensory information from the environment and sends 
projections to various effector regions to trigger the appropriate responses, therefore 
coordinating the behavioral response to threat (Davis, 1992; Davis and Shi, 2000; Pitkanen 
et al., 2000; Zarrindast et al., 2008). People affected by anxiety and depressive disorders 
experience exaggerated stress responses to threats and, therefore, dysfunctions in CeA 
functioning are hypothesized to play a critical role in the pathophysiology of such disorders 
(Etkin et al., 2009; Etkin and Wager, 2007; Shin and Liberzon, 2010).  
Here, we hypothesized that the PACAP/PAC1R system of the CeA contributes to 
the physiological and behavioral outcomes of chronic social defeat stress in rats. We first 
assessed the effects of chronic social defeat stress on PACAP expression in CeA, and then 
evaluated the functional role of PAC1R by knocking down the receptor in the CeA and 
assessing the effects on body weight change, anhedonia, and anxiety-like behavior 
following chronic social defeat stress. Finally, we investigated the effects of CeA PAC1R 
knockdown on local levels of corticotropin-releasing factor (CRF).  These findings support 
the notion that perturbations of the PACAP-PAC1R system may be involved in the aberrant 





Materials and Methods 
Subjects 
Experimental animals (intruders) were male Sprague Dawley rats weighing 301-
325 g upon arrival. Rats were single-housed in 10 1⁄2” x 19” x 8” wire-topped, plastic cages 
on a 12-hour reverse light cycle (lights off at 11:00 am), in an AAALAC-approved 
humidity- (≈60%) and temperature-(≈22 °C) controlled vivarium. Food (Envigo Teklad 
LM-485 7012 diet) and water were available ad libitum. Male Long-Evans retired breeders, 
400-600g upon arrival, were used as residents, and housed in 20” x 16” x 8 1⁄2” wire-
topped, plastic cages with ovariectomized Long-Evans females. Experimental tests were 
conducted during the rats’ dark cycle. Group sizes were as follow: Group 1: PACAP CeA 
immunohistochemistry (IHC), N= 7-12/group (total 19 rats); PACAP BNST IHC, N= 8-
12/group (total 20 rats). Group 2: AAV-PAC1R body weight, N= 9-12/group (total 43 
rats); AAV-PAC1R light-dark test, N= 9-10/group (total 39 rats); AAV-PAC1R saccharin 
intake, N= 8-9/group (total 35 rats); AAV-PAC1R CRF CeA IHC, N= 6-9/group (total 30 
rats).  Outliers were calculated independently for each experimental test as >3 standard 
deviations away from the jackknifed mean in the main dependent variables and excluded 
from further analyses, reason of the slight difference in group size across experiments 
within group 1 and group 2.  Procedures adhered to the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals and the Principles of Laboratory Animal Care 
and were approved by Boston University Medical Campus Institutional Animal Care and 





Chronic Social Defeat Stress 
The social defeat stress paradigm was modified from the resident-intruder model 
originally designed by Miczek and colleagues (Miczek, 1979; Tidey and Miczek, 1996). 
Social defeat sessions, which occurred once a day for at least 7 consecutive days, consisted 
of an intruder rat being placed into the home cage territory of an unfamiliar resident, which 
had previously been trained for high aggression (Fekete et al., 2009). Exposure lasted until 
the intruder submitted (i.e. assumed a submissive, supine position for >3 sec) or, if 
submission did not occur, up to 5 min, in which case the intruder was moved to a second 
resident and the session repeated.  Upon submission, the intruder was then placed inside a 
wire mesh enclosure (7 x 9 x 8.5 in) inside the resident cage for the remainder of the 30 
min session, which allowed auditory, olfactory, visual and limited physical contact 
(mouth/nose) but prevented injuries. Control rats were instead picked up, briefly handled, 
and then returned to their home cage for 30 min.    
For the PACAP immunohistochemistry experiment, rats were euthanized 10 days 
since the beginning of the daily social defeat sessions, 24 hr after the last session.  For the 
PAC1R knockdown study, behavioral tests were performed 6-8 hr after a social defeat 
session (see exact day in the description of each test). In addition, intruders’ body weight 
was recorded every 1 or 2 days.  
 
Viral Vectors 




rADCYAP1R1-shRNAmir) and a control virus (AAV1-CAG-GFP) were used (Vigene 
Biosciences, Rockville, MD). The PAC1R virus (here referred to as “AAV1-PAC1R”) was 
validated against the non-silencing control virus (here referred to as “AAV-GFP”), 
demonstrating a significant reduction in PAC1R protein expression in the CeA 3 weeks 
after viral infusion; Fig. 15).  
 
Intracranial microinfusion procedure 
Rats were anesthetized with 3-5% isoflurane and placed in a stereotaxic frame for 
bilateral AAV microinfusion into the CeA. Briefly, the tip of a 2 µl, 22-gauge Hamilton 
microsyringe was lowered 8.4 mm from skull surface into the CeA (AP -2.64, ML ±4.2) 
with the incisor bar set at -3.3 mm below the interaural line (flat skull), according to the 
Paxinos and Watson rat brain atlas (Paxinos and Watson, 2007). The AAVs were infused 
at a rate of 0.2 µl per minute over the course of 5 min (total volume: 1 µl per side). The 
needle was kept in place for an additional 10 min following infusion to prevent backflow. 
After surgeries, rats were allowed 3 weeks of recovery before the start of the chronic social 
defeat procedure to allow for maximum transfection.  
 
Viral placement: Viral transfection and placement was verified at the end of testing 
in a blinded manner. Rats with incorrect viral location or unsatisfactory spread (as assessed 






The light–dark transfer test was performed as described previously (Bourin and 
Hascoet, 2003) with minor modifications. The test apparatus was a Plexiglas rectangular 
box (50 x 50 cm) divided into two unequal compartments by a black Plexiglas partition 
with a small opening at the base. The smaller compartment (1/3) was kept dark (∼0 lx), 
while the larger compartment (2/3) was illuminated (20 lx) by a 75W light bulb located 
above. Rats were placed in the center of the dark compartment facing towards the partition 
to initiate the test session, after 7 consecutive defeats. The sessions were recorded and the 
latency to enter the light compartment as well as the percent (%) of time spent in the light 
compartment during each 10-min test session were scored by individuals blind to the 
treatments. 
 
Saccharin Intake Test 
To assess anhedonia, a two-bottle choice saccharin intake test was performed 
(Seiglie et al., 2015). Rats were first habituated to the presence of two drinking bottles (one 
containing 0.1% w/v saccharin, the other water). Test session was 1 hr in duration and 
occurred during the last hour of the light cycle, after 12 consecutive defeats. Water and 
saccharin consumption were measured by weighing the bottles before and at the end of the 






Perfusions and Immunohistochemistry: Rats were anesthetized with isoflurane and 
then transcardially perfused as previously described (Iemolo et al., 2013) 24 hr after their 
last social defeat session. Coronal 30 µm sections were cut on a cryostat, collected, and 
stored in cryoprotectant at −20 °C. Every sixth section (180 µm apart) of the entire CeA 
(Bregma: -2.0 to -3.0 mm) were chosen randomly and processed for 
immunohistochemistry. For all tests, free-floating sections were washed in Tris-buffered 
saline (TBS) after every incubation.  
PACAP staining: Sections were incubated in 0.3% hydrogen peroxide for 10 min 
to block endogenous peroxidases. Sections were blocked for 1 hr in 3% normal goat serum, 
0.4% Triton X-100 and then transferred into an anti-PACAP primary antibody (1: 8,000, 
Peninsula Labs, San Carlos, CA) in blocking solution for 24 hr at 4 °C. Sections were 
incubated in secondary antibody (1: 500, biotinylated anti-rabbit, Vector Laboratories, 
Burlingame, CA) in blocking solution for 2 hr at room temperature and then incubated in 
an avidin–biotin horseradish peroxidase ABC solution (Vector Laboratories, Burlingame, 
CA) in blocking solution for 1 hr.  Sections were then processed using a diaminobenzidine 
substrate kit (Vector Laboratories, Burlingame, CA) until reaction was complete and 
mounted onto slides and allowed to dry overnight. The following day, slides were 
dehydrated and coverslipped using DPX mountant (Electron Microscopy Sciences, 
Hatfield, PA).  
CRF staining: Slices were pretreated with 100 mM Urea (pH 9.5) for 10 min at 95 




solution (3% normal donkey serum, 0.4% Triton X-100) and subsequently incubated 
overnight at room temperature with a cocktail of two primary antibodies in blocking 
solution, an anti-CRF (1:200, Santa Cruz, Dallas, TX) and an anti-GFP (1:1,500, Abcam, 
Cambridge, MA). Sections were then incubated with the secondary antibodies donkey anti-
rabbit Alexa Fluor 488 and donkey anti-goat Cy3 (Jackson Immunoresearch, West Grove, 
PA) 1:400 in blocking solution for 2 hr at room temperature. Sections were mounted as 
discussed above.  
Densitometry: Using the Stereo Investigator software (MicroBrightField, 
Williston, VT), 10X objective pictures of sections containing either the CeA or the BNST 
were taken using an Olympus BX-51 microscope equipped with a Rotiga 2000R live video 
camera (QImaging, Surrey, BC), a three-axis MAC6000 XYZ motorized stage (Ludl 
Electronics, Hawthorne, NY), and a personal computer workstation.  CRF 
immunofluorescence pictures were captured through the Texas Red Filter cube (Olympus, 
Waltham, MA), while chromogen PACAP pictures were taken in bright field, both under 
a preset exposure and gain in order to standardize the images. For CRF in the AAV-PAC1R 
knockdown experiment, the presence of GFP signal was used to ensure appropriate viral 
transfection. All densitometry analyses were performed using ImageJ software (NIH). 
Traces of the CeA and background on brightfield images for PACAP were performed and 
mean optical density of signal was calculated by normalizing to the background signal. For 
CRF immunofluorescence, images were converted to 8-bit and adjusted using the auto 
threshold Triangle algorithm. Once converted, mean density of the tracing for 





Three-way analysis of variance (ANOVA) was used on body weight change data 
and on light-dark test data, with Defeat and AAV-shRNA as between-subject factors and 
Time as a within-subject factor. Two-way ANOVAs were used on saccharin intake and 
CRF density data, with Defeat and AAV-shRNA as between-subject factors. Pairwise post-
hoc comparisons were made using Newman-Keuls test; Student’s t-test was used when 
comparing two groups. Significance was set at p ≤ 0.05. The software/graphic packages 





Chronic social defeat increases PACAP levels in the CeA but not the BNST 
Brains from rats subject to chronic social defeat stress and their controls were 
collected 24 hr after 9 daily consecutive defeat sessions and PACAP immunoreactivity was 
assessed using immunohistochemistry. As shown in Figure 14A, chronic social defeat 
stress caused a significant increase in PACAP immunoreactivity in the CeA (t(17) = -2.99, 
p ≤0.05). Indeed, defeated animals showed a 23.3% increase in PACAP levels into the 
CeA, compared to non-defeated, control animals.  Conversely, chronic social defeat stress 
did not alter PACAP levels in the BNST (t(18) = 0.50, not significant (n.s.)), as shown in 
Figure 14B. Representative images of PACAP immunoreactivity are shown in Figure 14C 





Fig. 14 Effects of chronic social defeat stress on PACAP immunoreactivity in the CeA (A) 
and BNST (B) of rats. N= 7-12/group). Representative images for PACAP in the CeA (C) 
and BNST (D) of control and defeat animals. Bars represent Mean + SEM. ** p < 0.01 vs. 
Control. CeA; CeC, capsular part, CeL, lateral part, CeM, medial part. BNST; STLP, lateral 





PAC1R knockdown in the CeA reduces PAC1-positive cells in the CeA 
Brains from rats injected with AAV1-shPAC1 or AAV1-GFP into the CeA were 
collected 3 weeks after transfection and PAC1 immunoreactivity was assessed using 
immunohistochemistry. As shown in Figure 15A, AAV1-shPAC1 significantly decreased 
PAC1-positive cells in the CeA (t(10)= 4.07, p<0.01). AAV1-shPAC1 injected animals 
demonstrated a 35.7% reduction in PAC1-positive cells in the CeA compared to rats 





Fig. 15 Effects of bilateral microinfusion of an AAV1-shPAC1 into the CeA of rats on 
PAC1-positive cells in the CeA (A). N= 6/group. Representative image of viral spread 





PAC1R knockdown in the CeA attenuates chronic social defeat-induced reductions in 
body weight gain 
As shown in Fig. 16, chronic social defeat stress induced a reduction in body weight 
gain (white squares), compared to non-defeated, control animals (white circles) (Defeat: 
F(1,39)= 64.05, p ≤ 0.001). However, knockdown of PAC1R in the CeA was able to 
significantly attenuate such reduction across all the defeat period (grey squares), without 
affecting body weight change in non-defeated, control animals (grey circles) (PAC1R-




Fig. 16 Effects of bilateral microinfusion of an AAV1-shPAC1 into the CeA of rats on 
body weight change. N= 9-12/group. Bars represent Mean - SEM. * p ≤ 0.05, ** p  ≤ 0.01, 





PAC1R knockdown in the CeA blocks chronic social defeat-induced anxiety-like behavior  
Chronic social defeat induced anxiety-like behavior, as measured by a reduction in 
time spent in the light compartment of a light-dark test box, as shown in Fig. 17A. 
Knockdown of PAC1R in the CeA was able to reverse this heightened anxiety across the 
10 min of the test (PAC1-shRNA x Defeat: F(1,35)= 4.65, p ≤ 0.05). The inset of Fig. 17A 
shows the time spent in the light compartment by the 4 groups of animals in the cumulative 
10 min.  
Furthermore, knockdown of PAC1R in the CeA significantly reversed the increase 
in latency to first exit the dark compartment of the box induced by chronic social defeat, 





Fig. 17 Effects of bilateral microinfusion of an AAV1-shPAC1 into the CeA of rats in the 
light-dark box test on: (A) time spent in the light compartment, (B) latency to first leave 
the dark compartment. N= 9-12/group. Bars represent Mean + SEM. * p ≤ 0.05, ** p ≤ 




PAC1R knockdown in the CeA attenuates chronic social defeat-induced reductions in 
saccharin intake 
As shown in Fig. 18, knockdown of the PAC1R in the CeA significantly affected 
saccharin consumption selectively in rats exposed to chronic social defeat (PAC1-shRNA 





Fig. 18 Effects of bilateral microinfusion of an AAV1-shPAC1 into the CeA of rats on 





PAC1R knockdown in the CeA blocks social defeat-induced increases in CRF 
As shown in Fig. 19A, chronic social defeat caused an increase in CRF levels in 
the CeA (Defeat: F(1,26)= 7.30, p ≤ 0.05). However, the knockdown of PAC1R in the CeA 
significantly attenuated social defeat-induced increase in CRF (shRNA x Defeat: F(1,26)= 
4.12, p ≤ 0.05). Representative images of CRF immunohistochemistry in the CeA is shown 





Fig. 19 Effects of bilateral microinfusion of an AAV1-shPAC1 into the CeA of rats on 
CRF levels in the CeA (A). N= 6-9/group. Representative CRF staining images in the Def-
GFP (B) and the Def-shPAC1 (C) groups. Bars represent Mean + SEM. ** p ≤ 0.01 vs. 
NoDef-GFP. # p ≤ 0.05 vs. Def-GFP. CeA; CeC, capsular part, CeL, lateral part, CeM, 






The results of the present study reveal an important role for PACAP and PAC1R in 
regulating the physiological and behavioral responses to chronic stress.  Our first finding 
was that PACAP levels were significantly increased in the CeA of rats exposed to chronic 
social defeat stress. We then found that reducing PAC1R levels in the CeA via a viral 
vector containing a short hairpin RNA prevented the detrimental effects of chronic social 
defeat stress. Finally, we found that chronic social defeat stress-induced local increase in 
CRF levels was prevented by the CeA PAC1R knockdown.   
Our finding that PACAP immunoreactivity levels is higher in chronic social defeat 
rats is a significant one as, to our knowledge, selective increases in CeA PACAP levels as 
a result of chronic stress have not been reported before. importantly, this increase was 
observed 24 hr after the last social defeat session, suggesting that the effect is long-lasting 
and does not dissipate shortly after the end of the defeat session. Future experiments will 
be needed to more in depth assess the time-course of this effect, i.e. whether PACAP levels 
are already elevated in the CeA after the first defeat session (in which case it would be 
interpreted as a lack of habituation) or whether the PACAP increase requires multiple 
defeat sessions.   
PACAP levels were quantified using immunohistochemistry. As PACAP 
immunoreactivity in the CeA appears mainly as fibers, which form a dense net over a 
smaller number of PACAP positive cell bodies as previously shown (Hannibal, 2002; 
Koves et al., 1991; Piggins et al., 1996), it has been proposed that the majority of these 




brainstem nuclei, as it the case also for PACAP fibers of the BNST (Missig et al., 2014). 
Interestingly, no effect of chronic social defeat on PACAP levels in the BNST was 
observed. Since it was previously shown that a protocol of chronic variable stress is able 
to increase PACAP mRNA expression in the BNST but not in the CeA of rats (Hammack 
et al., 2009; Lezak et al., 2014), this apparent discrepancy may be due either to the different 
type of chronic stress used in the previous vs. this report (chronic variable stress vs. chronic 
social defeat stress) or to the fact that the previous reports assessed mRNA levels while 
this one assessed protein levels.  It may also be hypothesized that the PACAP protein being 
quantified here in the CeA may represent fibers originating from PACAP neurons of the 
BNST, as a BNST to CeA projection exists and has been shown to play a role in fear 
behavior; however, future experiments using tracing or viral techniques will be needed to 
confirm or disprove this hypothesis.  
To test the endogenous relevance of chronic stress-induced increase in PACAP 
levels within the CeA, a viral vector approach was used to test the effects of the knockdown 
of PACAP’s most selective receptor PAC1R, which is highly expressed in this area (Joo et 
al., 2004), on the outcomes of social defeat stress.  Chronic social defeat stress reduced 
body weight gain throughout the stress exposure period, which is consistent with previous 
findings (Bhatnagar et al., 2006; Pulliam et al., 2010). CeA PAC1R knockdown 
significantly attenuated the stress-induced reduction in body weight gain. Our data showing 
a role of PACAP in stress-induced body weight changes are in line with a previous study 
showing that chronic administration of a  PAC1R/VPAC2R antagonist into the BNST 




et al., 2014) and another one showing that PACAP knockout mice are significantly 
protected from the effects of chronic restraint stress on weight loss (Mustafa et al., 2015). 
Our results are consistent also with the report that intra-CeA infusion of PACAP causes 
significant reductions in body weight gain (Iemolo et al., 2015). CeA PAC1R knockdown 
had no effect on body weight gain in control, unstressed rats, indicating that the role of the 
PAC1R system in this specific brain area in the regulation of body weight is specific to 
changes due to stressful conditions, rather than pure ingestive behavior/metabolism.   Even 
though we did not measure food intake in this study, based on previous studies showing 
that in models of chronic stress the reduction in body weight gain is a result of stress-
induced hypophagia, we can speculate that CeA PAC1R knockdown likely acted by 
attenuating the reduction in food intake resulting from stress.  PAC1R knockdown in the 
CeA did not, however, completely block the effects of chronic social defeat stress on body 
weight change, suggesting that either other brain areas or other neurochemical systems are 
likely also involved in this phenomenon.  
Chronic stress, including chronic social defeat, causes anhedonic-like behavior (a 
core feature of depressive disorders, as measured for example by a reduction in the intake 
of sweet solutions (Sampson et al., 1991; Willner et al., 1987).  In this paper, we used a 
saccharin solution to test the effects of CeA PAC1R knockdown on the anhedonic-like 
response induced by chronic social defeat, without the confounding factor of the caloric 
content that sucrose would instead bring.  PAC1R knockdown in the CeA of defeated 
animals significantly increased saccharin intake compared to defeated rats which only 




as the PAC1R knockdown did not alter saccharin intake in control, unstressed animals. 
Interestingly, PAC1R knockdown tended to increase saccharin intake in defeeated animals 
to levels even higher than those of control, undefeated rats, but this effect did not reach 
statistical significance. Our results are in line with previous observations that PACAP-
deficient mice subject to chronic social defeat stress show attenuated depressive-like 
behaviors (Lehmann et al., 2013) and that central administration of PACAP induces 
depressive-like behaviors in rats, and strongly point at the CeA as a possible site of action 
for these effects, in addition to confirming a role for PAC1R (vs. VPAC receptors). 
PAC1R knockdown in the CeA also prevented the development of anxiety-like 
behavior in socially defeated animals, as evidenced by a reversal of the reduced time spent 
in the light compartment of a light-dark box and of the increased latency to first exit the 
dark compartment, induced by chronic social defeat.  The light-dark test is based on an 
approach-avoidance conflict between exploration of a novel environment and avoidance of 
brightly lit, open spaces and it is sensitive to states of stress as well as anxiogenic/anxiolytic 
drugs (Chaouloff et al., 1997; Crawley and Goodwin, 1980; Crawley, 1985; Merlo Pich 
and Samanin, 1989; Young and Johnson, 1991). Similarly to what observed with the other 
tests, PAC1R knockdown in the CeA had no effect on anxiety-like behavior in control, 
unstressed rats, suggesting that a heightened PAC1R activation tone, brought about by the 
chronic social defeat, is responsible for the detrimental behavioral outcomes. 
It is worth noting that the viral vector approach has clear advantages over the 
classical pharmacological approach in this specific case, in that it allows to skip the issue 




blockade of PAC1R during the course of the chronic social defeat exposure without the 
need for repeated intracranial injections. 
In this study, we found that chronic social defeat resulted in a significant increase 
in CRF levels in the CeA. This observation is in line with previous finding showing 
increases in CRF expression, CRF neuronal activation, and CRF receptor binding in the 
CeA following chronic psychosocial stress (Albeck et al., 1997) (Fuchs and Flugge, 1995).  
PAC1R knockdown in the CeA was able to significantly prevent the increases in CRF 
levels caused by social defeat, suggesting that CRF activation may be the downstream 
mechanism of the effects of PAC1R activation. While defeated-GFP animals have about a 
75% increase in CeA CRF compared to their non-defeated counterparts, defeated 
knockdown rats had roughly only a 10% increase from their non-defeated counterparts and 
most striking, 45% less CRF in the CeA compared to the defeated-GFP rats.  Notably, CeA 
PAC1R knockdown had no effect on CeA CRF levels in unstress controls. PACAP has 
been shown to increases CRF 5’ promoter activity in hypothalamic cell lines (Kageyama 
et al., 2007), and central administration of PACAP to augment CRF expression and CRF 
neuronal activation in the paraventricular nucleus of the hypothalamus (Agarwal et al., 
2005; Grinevich et al., 1997; Li and Sawchenko, 1998; Norrholm et al., 2005) as well as 
CRF peptide levels in the CeA (Dore et al., 2013). In addition, in PACAP knockout mice, 
the increase of hypothalamic CRF expression by prolonged stress are prevented (Stroth 
and Eiden, 2010), and central administration of a CRF receptor antagonist is able to block 
PACAP-induced anxiety- and depressive-like behavior in rats (Dore et al., 2013). PACAP 




close contact with CRF neurons in the CeA (Kozicz et al., 1997; Legradi et al., 1998; 
Missig et al., 2014).  Therefore, our results are in line with a proposed involvement of the 
local CRF system in the behavioral effects of PACAP in the CeA, although future 
experiments will be needed to directly test the relevance of this modulation in the context 
of chronic social defeat, as well as to understand whether PACAP affects local CRF release 
(perhaps via a presynaptic action on CRF terminals in the CeA) or it activates CRF 
neuronal cell bodies in the CeA (perhaps via a postsynaptic action) or both.  
Altogether, these results suggest that chronic social defeat recruits the 
PACAP/PAC1R system of the CeA, which mediates its negative physiological and 
behavioral consequences. Therefore, PACAP and PAC1R may represent important 
pharmacological targets for the treatment of stress-related psychopathologies such as 








The focus of my dissertation was to understand how the PACAP-PAC1R system 
modulates behavioral responses within neural circuits implicated in the stress response. In 
chapter 2, I comprehensively characterized the effects of PACAP on depressive-like 
behaviors in the rat using animal models of anhedonia, behavioral despair, and social 
withdrawal.  Central administration of PACAP induced a pro-depressant phenotype in rats, 
with i.c.v. PACAP causing increased current threshold for ICSS which can be blocked by 
co-administration of the PAC1R antagonist PACAP(6–38). PACAP reduced the 
consumption and preference for a saccharin solution and reduced social interaction. In the 
context of the stress response, the capacity to experience pleasure is actively suppressed 
during stress, which may underlie the effects of exogenous i.c.v. PACAP.  
In chapter 3, I demonstrated the contribution of the PACAP-PAC1R system of the 
CeA and BNST in increasing heightened arousal to noise bursts and that activation of 
PAC1R in these regions is necessary for startle sensitization.  The central findings in the 
study were that PACAP microinfusion into either the CeA or BNST increased acoustic 
startle and that these effects are mediated by PAC1R, as evidence by microinfusion of VIP 
having no effect on ASR in the same brains regions. Additionally, PAC1R/VPAC2R 
antagonism using PACAP(6-38) into either the CeA or the BNST did not affect baseline 
ASR, but it blocked footshock-induced sensitization of ASR when administered prior to 




PACAP levels in both the CeA and BNST while VIP levels remain unchanged in response 
to the shocks. Altogether, this evidence strongly indicates a critical role for the PACAP 
system of the CeA and BNST in the behavioral response to stress. 
In chapter 4, I investigated the neuroanatomical and molecular mechanisms by 
which PACAP mediates the behavioral and physiological effects of chronic social defeat 
stress.  In utilizing the chronic social defeat model, animals that underwent the protocol 
exhibited increased PACAP density in the CeA but not in the BNST. Consequently, to test 
whether PACAP signaling in the CeA, via PAC1R, mediated the physiological and 
behavioral effects of chronic stress, I injected a shRNA PAC1R virus in the CeA to 
knockdown PAC1R. Knockdown of PAC1R in the CeA significantly blunted the reduction 
in body weight gain, blocked defeat-induced increases in CRF, reduced anhedonia, and 
decreased anxiety-like behavior in chronic social defeat animals, while it had no effect on 
controls. Our data strongly suggest that dysregulation of the PACAP/PAC1R system of the 
CeA stress may mediate the behavioral outcomes of chronic social defeat stress. 
While acute stress PACAP/PAC1R signaling may increase anxiety-like responding 
to facilitate the response necessary to escape threat (i.e. enhance startle), we hypothesize 
that a prolonged PACAP/PAC1R system activation in the CeA which does not habituate 
and therefore persists in response to chronic stress may lead to the long-lasting 
pathophysiological changes seen in stress-related disorders. Together, our results suggest 
that the hyperactivity of the PACAP/PAC1R system may contribute to the pathophysiology 
of anxiety- and depressive-like symptomatology associated with the disease. 




PAC1R in mediating depressive- and anxiety-like behaviors resulting from the exposure to 
stressors. Additional studies will, however, be needed to better understand the neuronal 
PACAP projections involved in the observed effects, both upstream and downstream of 
the CeA and the BNST. Indeed, while the current studies have investigated the effects of 
PACAP within the CeA, of the source of PACAP to the CeA may either be local or 
originate from sources outside of the CeA. It has been shown that PACAP neurons 
originating from the PBn innervate the CeA, with PACAP immunoreactivity in the CeA 
being significantly diminished after PBn lesions and, therefore, this projection likely 
represents a critical source (Missig et al., 2014). This pathway is also crucial in the 
processing of acute and chronic pain, with models of neuropathic pain resulting in 
enhanced PBn-CeA transmission and increased CRF mRNA expression and 
immunoreactivity (Veinante et al., 2013).  
We are currently performing preliminary studies to directly test the functional 
relevance of the PBn-CeA PACAPergic pathway on the anxiety-like behavior and the 
behavioral response to stress. PACAP-Ires-Cre mice, which have Cre recombinase 
expression driven by the endogenous PACAP gene (Krashes et al., 2014), will allow us to 
use a chemogenetic approach involving Cre-dependent DREADD viruses. PACAP-Ires-
Cre mice will be injected with an AAV-DIO-hM3D virus into the PBn and, after viral 
transfection, the effects of the DREADD ligand Clozapine-N-Oxide (CNO) microinfused 
into the CeA will be assessed on anxiety- and depressive-like behaviors. Our preliminary 
findings appear to support the notion that PACAPergic PBn-CeA neurons mediate anxiety-




The downstream signaling effects of PACAP are also not fully understood. 
Increasing evidence suggest the involvement of CRF systems in some of the effects of 
PACAP. I.c.v. infusion of PACAP increases CRF mRNA in the PVN (Dore et al., 2013; 
Grinevich et al., 1997) and CRF immunoreactivity in both the PVN and CeA (Dore et al., 
2013). In addition, we have shown that CRF receptor antagonism is able to block PACAP-
induced anxiety- and depressive-like behaviors (Dore et al., 2013).  Furthermore, PACAP-
deficient mice demonstrate blunted stress-induced c-Fos expression in CRF neurons of the 
PVN (Tsukiyama et al., 2011).  Importantly, PACAP-expressing neurons directly synapse 
on CRF-expressing neurons in the BNST and PVN (Hammack et al., 2010). Our finding 
that PAC1R knockdown blocks defeat-induced increases in CRF in the CeA further 
supports this hypothesis. Together, these findings suggests that PACAP and its receptors 
in the brain are involved in the positive regulation of CRF gene expression and that CRF 
activation may be necessary for PACAP’s effects on the behavioral stress response.  This 
potential downstream effects of PACAP needs, however, to be more comprehensively 
studied, , as the exact brain sites where this interaction would occur is not currently known, 
and neither is the exact mechanism or the specific physiological/pathological instances in 
which the two systems do or do not interact. 
Another possible downstream mechanism that may regulate the behavioral effects 
of PACAP may involve the melanocortin system. Melanocortins, such as α-MSH, and the 
melanocortin 4 receptor (MC4R) are highly expressed in the CeA and the role of this 
system in the modulation of anxiety-like behaviors has emerged. Microinjections of a 




the amygdalar α-MSH/MC4R system induces anxiety-like behavior (Kokare et al., 2005). 
Furthermore, footshock stress increases MC4R gene expression in the amygdala and 
hypothalamus (Yamano et al., 2004), while MC4R antagonism prevents the behavioral 
consequences of restraint stress and footshock (Chaki et al., 2003; Vergoni et al., 1999). In 
order to determine whether the PACAP and melanocortin systems interact in the CeA, we 
demonstrated that pretreatment in the CeA with the MC3R/MC4R antagonist SHU9119 
successfully blocked intra-CeA PACAP-induced anxiety-like behavior (Iemolo et al., 
2016). Our results demonstrated that activation of the PACAP system of the CeA induces 
anxiety-like behavior via MC4R, providing novel insights into this neuropeptide system as 
a mechanism for modulating the behavioral responses to stress.  Future experiments should 
be done, using in situ hybridization, to parse out how PACAP in the CeA directly effects 
melanocortin gene expression. 
The microcircuit of the CeA as it pertains to PACAP effects remains not fully 
understood. Here we propose some of the mechanisms through which PACAP may mediate 
the behavioral effects of stress via the activation of the local CRF system.   
Within the CeL subdivision of the CeA, two functionally distinct neuronal 
GABAergic subpopulations have been described, which form a local inhibitory circuit that 
inhibits the output neurons of the CeM subdivision: “CeLon” neurons and “CeLoff” neurons 
(Ciocchi et al., 2010). “CeLoff” neurons , which express predominately protein kinase C δ 
(PKC-δ+) (Haubensak et al., 2010), are inhibited by “CeLon” neurons and in turn project 
to CeM output neurons, inhibiting them. CeM neuronal activity which is therefore under 




has been shown to activate CeM neurons and inhibit “CeLoff” neurons (Ciocchi et al., 
2010).  We propose that a population of “CeLon” neurons expressing CRF also express 
PAC1Rs. “CeLon” neurons, whose activation removes the tonic inhibition on output CeM 
neurons, receive glutamatergic inputs, so we speculate that one of these afferents originates 
in the PBn and co-expresses PACAP (Missig et al., 2017), in line with the hypothesis that 
CeA CRF+ neurons are regulated by brainstem PACAP signaling. It is unlikely that 
PACAP may modulate CRF+ neurons belonging to the “CeLoff” population, as these 
neurons have been shown to rarely co-express CRF (McCullough et al., 2018).  A 
complementary or alternative hypothesis is that PACAP may increase CRF release by 
acting on presynaptic PAC1R in CRF terminals making synapsis on “CeLon” neurons, 
therefore activating them.  “CeLon” CRF+ neurons can elicit anxiety-like behavior either 
by inhibiting “CeLoff” neurons, thereby removing the brake on CeM neurons, or 
theoretically also by projecting directly to downstream regions, such as the BNST and the 
brainstem nuclei.  Finally, PACAP may modulate CeM neurons directly, either by 
potentiating glutamate release onto them via a presynaptic PAC1R-mediated action, or by 
activating them via postsynaptic PAC1Rs.  A schematic of this hypothetical circuit can be 
found in Figure 20.  
These findings collectively propose the PACAP system of the extended amygdala 
as a master regulator of stress-induced psychopathology.  Research into the neurobiological 
mechanisms underlying the pathological response to stress will improve our understanding 
of the etiology of stress-related disorders and facilitate the development of novel 




Fig. 20 Hypothetical model of PACAP regulation of CeA microcircuits.  [Figure was 
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